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SUMMARY 
Hepatocellular carcinoma (HCC) is one of the most frequent cancers worldwide and still a 
major cause of cancer-related death. Despite intensive research, therapy options are limited 
leaving an urgent need to develop new strategies. Recently, targeting cancer cell lipid and 
cholesterol metabolism came into focus especially in the context of HCC. Aberrantly 
increased cholesterol levels cause excessive proliferation, membrane-related mitogenic 
signaling and a reduction in cell stiffness - factors that favor tumor progression, malignancy 
and invasive potential. Yet, targeting cholesterol metabolism for cancer therapy is still 
challenging, leading to a sustained lack of effective therapy options. The V-ATPase inhibitor 
archazolid was recently implicated in cholesterol metabolism. We report for the first time a 
novel therapeutic potential of V-ATPase inhibition in cancer by influencing the mechanical 
phenotype of cancer cells thereby reducing oncogenic Ras signaling. Archazolid inhibits low 
density lipoprotein (LDL) uptake and induces lysosomal cholesterol trapping, which depletes 
free cholesterol from the cells and thus leads to an increase in cell stiffness and membrane 
polarity of cancer cells, while non-malignant hepatocytes remain unaffected. The deficiency 
of cholesterol in the plasma membrane decreases fluidity and leads to an inhibition of 
membrane-related Ras signaling resulting in decreased proliferation in vitro and in vivo. By 
simultaneous application of the lipid-lowering drug simvastatin, a well characterized inhibitor 
of de novo cholesterol synthesis, a potential escape mechanism by enhanced cholesterol 
production is prevented, thereby leading to a synergistic growth inhibition in vitro. Hence, we 
present a novel link between cell biophysical properties and proliferative signaling selectively 
in malignant HCC cells, which can be targeted synergistically by V-ATPase inhibition and 
blocking cholesterol synthesis, thus building the basis for an attractive and innovative 
strategy against HCC (Fig 1). 
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Figure 1 Effects of a combination therapy approach in HCC Upon inhibition of the V-ATPase by 
Archazolid (arch), LDLR internalization and acidification of the endo-lysosome is inhibited, causing 
subsequent accumulation of cholesterol within the lysosomes. Due to blocking the conversion of HMG-
CoA to mevalonate by simvastatin (sim) , de novo synthesis of free cholesterol is inhibited. The lack of 
free cholesterol leads to cholesterol depletion of the membrane and subsequently to disruption of 
cholesterol-enriched microdomains and a change in membrane properties. As a consequence, 
cholesterol microdomain-dependent Ras cannot be activated anymore and downstream signaling is 
inhibited, leading to reduced proliferation and tumor growth. Mev Mevalonate, GPP 
geranylpyrophosphate, FPP farnesylpyrophosphate, Sq squalene, Lano lanosterol, GEF guanosyl-
exchange factor, GAP GTPase activating protein, LDL(R) low density lipoprotein (receptor) 
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1. INTRODUCTION 
1.1. Hepatocellular carcinoma 
1.1.1. Risk factors and therapy options 
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, one 
of the most frequent cancers worldwide and a major cause of cancer-related death 
(1-3). The global incident rate of HCC is disproportionate with an increased amount 
of cases in areas with a high occurrence of hepatitis infections and poor medical 
care. However, the frequency in the western world is constantly increasing, caused 
by migration from virus-endemic regions and changes in lifestyle promoting HCC risk 
factors (4).  
 
Figure 2 Global incidence of liver cancer Incidence of liver cancer in both sexes by geographical 
region. Age-standardized rate (ASR) of incidence is depicted in blue as a rate of new cases per 
100,000 persons per year. Graphic sourced from GLOBOCAN 2012 (5).  
 
The principal causes for the development of HCC are chronic liver diseases and 
cirrhosis, which are mainly promoted by infection with hepatitis B or C virus. Yet, 
besides viral hepatitis, alcohol consumption accounts for 40-50 % of HCC cases in 
Europe. Further conditions like diabetes, obesity, non-alcoholic fatty liver disease, 
smoking, aflatoxins, hereditary hemochromatosis or male sex increase the risk of 
developing the malignancy (2).  
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Despite intensive research, the prognosis remains poor, owing to late-stage 
diagnosis and limited therapy options. The first choices in treatment of early-stage 
HCC are liver transplantation and surgical resection; whereas the only approved 
systemic therapeutic option for late-stage HCC is the kinase inhibitor sorafenib, 
which extends the median overall survival by 2.8 months (6,7). Additionally, 
recurrence after transplantation and severe side effects of sorafenib display major 
problems in treatment.  
1.1.2. Biomarkers and new strategies for treatment 
In order to fight HCC, numerous studies are ongoing to reveal new therapeutic 
strategies and to improve diagnostic possibilities. A promising approach is focusing 
on the metabolic changes that lead to the malignancy, but also are caused by the 
disease. Several biomarkers have been proposed to serve for surveillance of high-
risk patients in diagnosing HCC, such as serum concentrations of α-ferroprotein, des-
gamma carboxythrombin, inflammation markers and many more (4). Several studies 
also report alterations in HCC lipid metabolism that might serve as biomarkers, 
especially deregulations in fatty acid oxidation and cholesterol metabolism have been 
observed (4,8). Targeting cancer lipid and cholesterol metabolism pathways has 
come into focus lately, as deregulation has been reported in various types of cancer 
cells and patient blood samples (9).  
Interestingly, the vacuolar-type ATPase (V-ATPase), a protein in the focus of our 
research, has been implicated in cholesterol metabolism recently (10) and our group 
has already shown that V-ATPase inhibition displays anti-cancer properties (11-13). 
Hence, the V-ATPase seems to be an interesting new target in the treatment of HCC. 
1.2. The V-ATPase in light of cancer treatment 
1.2.1. Physiological structure and function of the V-ATPases 
V-ATPases are large multi-subunit protein complexes expressed in a variety of 
cellular membranes, especially in the endo-lysosomal system. The V-ATPases are 
ATP-dependent proton pumps and are primarily responsible for maintaining pH 
homeostasis by regulation of the proton concentration in intracellular organelles. 
Basically, the V-ATPase consists of two functional domains (Fig 3): the V1 domain, 
which is located at the cytosolic side of the membrane and exerts ATP hydrolysis to 
generate energy for the second domain, and the V0 domain, which is integrated in the 
membrane and responsible for proton translocation (14,15). Both domains are 
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composed of a variety of different smaller subunits. In V1, the A and B subunits 
create the catalytic sites for ATP hydrolysis and the C-H subunits form central and 
peripheral stalk. Following energy generation, the V0 domain moves in a rotatory 
fashion and protons bound to the domain can be released to the luminal side (14,16).  
 
Figure 3 Structure of the V-ATPase The V-ATPase consits of two functional domains: the V1 domain 
and the V0 domain. The cytosolic V1 domain is built by eight subunits A-F with A and B forming the 
catalytic sites for ATP hydrolysis (one site per AB heterodimer), C-H forming the peripheral stalk that 
keeps V1 in its place and DF forming the central stalk which couples the energy to the V0 domain.The 
membrane integral V0 domain consists of subunits a,d,e and 4 copies of c. The c subunits form a 
membrane integral proteolipid ring and subunit a contains a hemichannel for proton (H
+
) translocation. 
The proteolipid ring rotates subsequently to engergy generation in V1 domain, thereby enabling proton 
release to the luminal side. Illustration according to the model of Forgac et al. 2007 (14). 
 
Consequentially to their function as proton pumps, V-ATPases play a crucial role in 
physiological processes like receptor-mediated endocytosis, membrane trafficking 
and recycling. Specialized cells also express the V-ATPase on their plasma 
membrane in order to acidify the extracellular space, important e.g. in the renal tube 
or in the process of bone resorption (14,17). 
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1.2.2. The V-ATPase in cancer 
Expressing V-ATPase at the plasma membrane is also a feature reported for cancer 
cells. The extracellular space of tumors has been shown to display low pH provided 
by the V-ATPase, a metabolic status favoring migration and invasion of several 
cancer types including HCC. In this regard, V-ATPase expression at the plasma 
membrane was correlated with metastatic potential of cancer cells. (17-22)  
Recently, the V-ATPase has emerged as promising anti-cancer target as inhibition 
leads to apoptosis induction of a variety of cancer cells. In this regard, our group 
could demonstrate that inhibition of epidermal growth factor receptor (EGFR) and 
transferrin receptor recycling by blocking V-ATPase function leads to an inhibition in 
cancer cell migration and induction of apoptotic cell death in highly metastatic cancer 
cells (11,12,23). Interestingly, Hamm et al. recently found first evidence that  
V-ATPase inhibition affects cholesterol homeostasis in cancer cells (24), a function 
that provides the possibility to be exploited for treatment of cancers relying on altered 
lipid metabolism. 
1.2.3. V-ATPase inhibitors 
As it has been shown that V-ATPase function is important for migration and survival 
of various cancer cells, inhibitors of the proton pump came into focus for anti-cancer 
therapies.  
Since the early 1980s, the plecomacrolides bafilomycin and concanamycin which 
were isolated from Streptomyces species have been known to inhibit the V-ATPase. 
While bafilomycin was the first described inhibitor, concanamycin showed higher 
specificity. The plecomacrolides bind to the c subunit of the proteolipid ring thereby 
preventing rotation and proton translocation. (25,26) Further research in the late 
1990s revealed the benzolactone enamides (e.g. salicylihalamide, apicularen) as 
inhibitors with IC50 values in the nanomolar range (27). Efforts to simplify structures of 
V-ATPase inhibitors brought forth the synthetic indolyls, which are widely used for 
research due to the possibility of modification for different biophysical approaches 
(28,29).  
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Another highly potent inhibitor is archazolid (Fig 4), a myxobacterial secondary 
metabolite with IC50 values in the low nanomolar range. Archazolid was isolated from 
the strains Archangium gephyra and Cystobacter violaceus and its total synthesis 
has been published several years ago (30-33). Archazolid is a macrocyclic lactone 
that binds to the equatorial region of the c subunit thereby inhibiting rotation and 
proton translocation similar to plecomacrolides (27). As it is an inhibitor with high 
specificity and affinity as well as proven anti-cancer activity, we used it as a tool for 
studying  
V-ATPase in HCC.  
 
Figure 4 Structure of archazolid A adapted from Huss et al. 2009 (27). 
 
1.3. Cholesterol metabolism  
Cholesterol is a molecule of central importance in the human body and as such has 
been intensively studied for a long time. It is an essential component of the 
membrane barrier influencing its fluidity, the function of membrane proteins and 
transmembrane signaling processes (34). Furthermore, cholesterol is a precursor for 
steroids and bile acids, which have important biological roles in signal transduction 
and regulation of other lipids. Owing to its various functions, de-regulation in 
cholesterol homeostasis is implicated in many serious diseases like atherosclerosis, 
diabetes and cancer (34,35). Hence, cholesterol metabolism is extensively regulated.  
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1.3.1. Cellular cholesterol homeostasis 
In principle, cellular cholesterol homeostasis is regulated by synthesis, influx and 
efflux. Eukaryotic cells can synthesize cholesterol in the endoplasmatic reticulum 
(ER), utilizing the mevalonate pathway starting from Acetyl-CoA. The rate-limiting 
step of the de novo synthesis is the reduction of HMG-CoA to mevalonate catalyzed 
by the HMG-CoA reductase (HMGCR), the direct target of statins. (34-36) Apart from 
their indication as lipid-lowering agents, statins were also tested in several studies for 
the use as anti-cancer agents, but until now with controversial outcome (37,38). 
 
Figure 5 Cholesterol synthesis pathway Starting from Acetyl-CoA, HMG-CoA is synthesized via 
multiple enzymatic reactions. The subsequent reduction of HMG-CoA to mevalonate, catalyzed by the 
HMGCR, is the rate-limiting step of the following synthesis. After further multiple reactions, farnesyl-PP 
is synthesized, which is used to generate additional important metabolites with distinct cellular 
functions. Cholesterol is synthesized in a complex pathway facilitating demethylations and double 
bond reductions in about 20 different reactions from lanosterol. Cholesterol is then further metabolized 
or used as membrane building block. Illustrated according to Ikonen and Thurnher (34,36). Dashed 
lines between molecules (blue boxes) indicate multiple reactions; PP pyrophosphate; grey boxes list 
sequential functions and products. 
 
The second important way for cells to increase their cholesterol content is the 
internalization of cholesterol-containing lipoproteins mainly via the low-density 
lipoprotein receptor (LDLR) pathway. Dietary cholesterol is absorbed in the small 
intestine and transported to hepatocytes that provide the body with very low-density 
lipoprotein (VLDL). In the circulation VLDL is processed to LDL, which can bind to the 
LDLR on the surface of cells. The complex is then internalized and cleaved in the 
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acidic environment of the endo-lysosomal system. The LDLR is recycled back to the 
cellular surface and free cholesterol is released into the cytosol. (35,39)  
 
Figure 6 LDL internalization LDL (green) from the circulation binds to the LDLR on the outer surface 
of the plasma membrane. The complex is internalized into the endo-lysosomal system. In the acidic 
environment of the lysosome, created by the V-ATPase, LDL dissociates from the receptor, is cleaved 
and free cholesterol (blue) is released into the cytosol.  
 
While excess cholesterol is esterified for intracellular storage or externalized, free 
cholesterol is further metabolized or integrated into membranes. 
1.3.2. Cholesterol - an integral membrane molecule with multiple functions 
Cholesterol is one of the main components of mammalian cell membranes with a 
molar proportion of up to 50 % in the plasma membrane (40). Probably the most 
important function of membrane cholesterol is to modulate biophysical properties by 
increasing order. Integration of cholesterol between phospholipids decreases mobility 
of phospholipids and raises the packing density within the membrane, thereby 
influencing mechanical strength and fluidity (41).  
Yet, cholesterol is heterogeneously present within intracellular membranes, while  
40-90 % of cellular free cholesterol is integrated into the plasma membrane, 
mitochondria for instance only contain about 0.5-3 % of the cholesterol concentration 
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and golgi membranes show intermediate levels (41-43). This indicates additional 
functions for membrane cholesterol. 
There exist small areas within membranes that are especially rich in cholesterol and 
sphingolipids and display a very high membrane order, the lipid-rafts. These distinct 
microdomains also contain transmembrane and membrane-integrated proteins 
essentially involved in signal transduction. (44,45) Lipid-rafts have been shown to 
regulate activity of enzymes and to influence ion channels and membrane receptors, 
thereby modulating proliferation and signaling (40,41,45,46).  
1.3.3. Implication of cholesterol metabolism in cancer 
Given the functions of cholesterol, it is not surprising that alterations in cholesterol 
metabolism have been shown both to occur in and to influence cancer cells. 
Cholesterol is an important player in the development of malignancy. High 
cholesterol levels in cancer cells are known to be beneficial for tumor progression 
and drug resistance and it has been reported that alterations in cholesterol levels of 
primary tumor cells and HCC cell lines were linked with chemotherapy resistance and 
protection from apoptosis (9,47).  
Lately, increasing evidence suggests that the loss of cell stiffness correlates with the 
malignancy and invasive potential of cancer cells. Studies have shown that cancer 
cells are softer than their non-malignant counterparts, which seems to correlate with 
metastasis, invasion and tumor stage (40,46). Furthermore evidence increases that 
de-regulated cholesterol metabolism in cancer cells influences intracellular signaling 
(48,49). Cholesterol metabolism therefore emerged as a promising target in the 
combat to find new anti-cancer treatment options. 
1.4. Oncogenic Ras signaling in HCC 
The small GTPase Ras is a well-known oncogene mutated in 20 % of all tumors, and 
has been shown to be an oncogene excessively activated in HCC (50,51). 
Interestingly, recent research suggests that cholesterol content of the plasma 
membrane influences signaling pathways, like e.g. Ras signaling, and therefore 
might be of interest when considering aberrant Ras signaling in cancer (52).  
In HCC, genetic mutations in Ras or the downstream effector Raf are rare compared 
to other tumor types; however activation of the Ras downstream pathways commonly 
occurs through dysregulation of Ras activators or inhibitors (53,54). In general, 
increased activity of Ras displays poor prognosis for cancer patients. 
INTRODUCTION  20 
The activation state of Ras is dependent on the binding status of guanosine 
diphosphate (GDP) or guanosine triphosphate (GTP). Inactive Ras is bound to GDP, 
which is exchanged for GTP by guanosyl-exchange factors (GEFs) such as SOS. 
Activation of GEFs is for example facilitated by the binding of growth factors to their 
receptor on the cell surface. GEFs are then recruited to the plasma membrane to 
activate Ras. GTP-bound Ras in turn activates various downstream signaling 
cascades like the MAPK or PI3K pathway, which ultimately lead to transcription of 
cell proliferation-, migration-, survival-, differentiation- and mesenchymal-epithelial-
transition-related target genes (50,53). 
 
Figure 7 Activation of Ras downstream signaling Upon binding of a growth factor like EGF to its 
respective receptor on the cell surface, receptor downstream signaling is initiated. In case of the EGF, 
the receptor dimerizes and undergoes autophosphorylation. Subsequently, the guanosyl-exchange 
factor (GEF) SOS and the adapter protein GRB2 are recruited. GEFs exchange GDP bound to Ras for 
GTP, which leads to an activation at cholesterol-rich membrane sites. Activated Ras in turn activates 
various downstream signaling pathways that lead to distinct functions, as depicted in the respective 
boxes. Deactivation of Ras is facilitated by GTP-ase activating proteins (GAPs) that exchange GTP for 
GDP. Blue circles represent cholesterol. Illustration adapted from Delire et al. 2015 and Downward et 
al. 2013 (50,53). 
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1.5. Aim of the study 
Our group has previously introduced the potent V-ATPase inhibitor archazolid as an 
interesting and effective anti-cancer agent and unraveled different aspects of its 
mechanism of action (11-13,23). Interestingly, there is initial evidence now that  
V-ATPase inhibition affects cholesterol homeostasis in cancer cells (24).  
In the present study we aim to specifically target cancer cell cholesterol metabolism 
by archazolid single treatment and furthermore in a combination therapy approach 
together with simvastatin. We want to 
  
 analyze the effect of V-ATPase inhibition on cell biophysical properties 
 investigate the role of V-ATPase in cholesterol regulation  
 assess possible consequences on cell survival  
 and reveal underlying mechanisms 
 
in order to find new strategies for the treatment of HCC (Fig 8).  
 
Figure 8 Study objectives The study aims to use archazolid A as a tool to investigate the influence of 
V-ATPase inhibition on cellular biophysics, cholesterol metabolism and cell survival in order to find 
new treatment strategies for HCC. 
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2. MATERIALS AND METHODS 
2.1. Materials 
2.1.1. Compounds 
The myxobacterial compound archazolid A was provided by Rolf Müller (Saarland 
University) and simvastatin was purchased from Sigma-Aldrich. The compounds 
were dissolved to 10 mM stock solutions in DMSO and stored at -20 °C. As the final 
DMSO concentration in the experiments did not exceed 0.1 %, possible DMSO side 
effects could be excluded. 
2.1.2. Inhibitors, reagents and technical equipment 
Table 1 Biochemicals, dyes, inhibitors, kits and cell culture reagents 
Reagent Producer 
5x siRNA Buffer DharmaconTM, GE Healthcare, USA 
AmaxaTM Cell Line NucleofectorTM Kit T Lonza Cologne AG, Cologne, Germany 
Amplex® Red Cholesterol Assay Kit Molecular Probes Inc., Thermo Fisher, 
Eugene, OR, USA 
BC Assay reagent  Interdim, Montulocon, France  
Bovine serum albumin   Sigma-Aldrich, Taufkirchen, Germany 
Cell-Titer BlueTM Promega, Madison, WI, USA 
Collagen A/G Biochrom AG, Berlin, Germany 
Complete® EDTA free Roche Diagnostics, Penzberg, 
Germany 
Crystal violet Carl Roth, Karlsruhe, Germany 
Dithiotherithol (DTT) AppliChem, Darmstadt, Germany 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
PAA Laboratories, Pasching, Austria 
DMSO Sigma-Aldrich, Taufkirchen, Germany 
EDTA Carl Roth, Karlsruhe, Germany 
EGTA Sigma-Aldrich, Taufkirchen, Germany 
EGF Peprotech, Rocky Hill, USA 
FCS Biochrom AG, Berlin, Germany 
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FluorSaveTM Reagent Merck, Darmstadt, Germany 
Formaldehyde 16 %, ultrapure Polysciences, Eppelheim, Germany 
GlutaMAXTM Life Technologies, Thermo Fisher, 
Carlsbad, CA, USA 
HepaRG™ Thaw, Plate, & General Purpose 
Medium Supplement 
Life Technologies, Thermo Fisher, 
Carlsbad, CA, USA 
HepaRG™ Maintenance/Metabolism 
Medium Supplement 
Life Technologies, Thermo Fisher, 
Carlsbad, CA, USA 
High-Capacity cDNA Reverse Transcription 
Kit 
Applied Biosystems, Foster City, CA, 
USA 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
Igepal CA 630 (Nonidet P 40) Sigma-Aldrich, Taufkirchen, Germany 
Na3VO4 ICN Biomedicals, Aurora, Ohio, USA 
NaCl Sigma-Aldrich, Taufkirchen, Germany 
NaF Merck, Darmstadt, Germany 
Non-fat dry milk powder (Blotto) Carl Roth, Karlsruhe, Germany 
Page-Ruler TM Prestained Protein Ladder Fermentas, St. Leon-Rot, Germany 
Penicillin/Streptomycin (P/S) PAA Laboratories, Pasching, Austria 
PFA Sigma-Aldrich, Taufkirchen, Germany 
PMSF Sigma Aldrich, Taufkirchen, Germany 
Polyacrylamid Carl Roth, Karlsruhe, Germany 
PowerUp TM SYBR Green Master Mix  Applied Biosystems, Foster City, CA, 
USA 
Propidium iodide Sigma-Aldrich, Taufkirchen, Germany 
Qiagen RNeasy Mini Kit Qiagen, Hilden, Germany 
Ras Activation Kit ab128504 Abcam, Cambridge, UK 
Sodiumdodecylsulfate (SDS) Carl Roth, Karlsruhe, Germany 
TCE Sigma-Aldrich, Taufkirchen, Germany 
Tris Base/HCl Sigma-Aldrich, Taufkirchen, Germany 
Trisodium citrate dicydrate Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Tween 20 Bio-Rad, Munich, Germany 
VECTASTAIN Elite ABC HRP Kit Vectorlaboratories, Burlingame, CA, 
MATERIALS AND METHODS  25 
(Peroxidase, Universal) USA 
ImmPACT AEC Peroxidase (HRP) 
Substrate 
Vectorlaboratories, Burlingame, CA, 
USA 
William’s E-Medium  Life Technologies, Thermo Fisher, 
Carslbad, CA, USA 
 
2.1.3. Technical equipment 
Table 2 Technical equipment 
Technical equipment Producer /Distributor 
7300 Real Time-PCR System applied Biosystems, ThermoFisher 
PCR, Scientific, Waltham, MA, USA 
Axiovert 25 Zeiss, Oberkochen, Germany 
BD FACS CantoTM II BD Biosciences, Heidelberg, Germany 
Canon EOS 450C camera Canon, Tokyo, Japan 
ChemiDocTM Touch Imaging system  Bio-Rad, Hercules, CA, USA 
Consort Electrophoresis Power Supply 
E835 
Sigma-Aldrich, Taufkirchen, Germany 
Curix 60 Agfa, Cologne, Germany 
ibiTreat μ-slide 8-well ibidi GmbH, Munich, Germany 
Leica-SP8 confocal microscope Leica Microsystems Inc., IL, USA 
Mikro 22R centrifuge Hettich, Tuttlingen, Germany 
Mini-PROTEAN 3 Bio-Rad, Munich, Germany 
Nanodrop® ND-1000 Peqlab, Wilmington, DE, USA 
NucleofectorTMII Device Lonza, Basel, Switzerland 
Odyssey 2.1 LI-COR Biosciences, Lincoln, NE, USA 
Olympus CK30 and BX41 Olympus Deutschland GmbH, Hamburg, 
Germany 
Primus 25 advanced® Thermocycler  PeQlab, Erlangen, Germany 
PVDF Blotting Membrane 0,2 µm AmershamTM HybondTM, GE Healthcare, 
Life science, Germany  
QuantStudio® 3 Real-Time Instrument 
(96-Well 0.1 ml Block) 
applied biosystems, ThermoFisher PCR, 
Scientific, Waltham, MA, USA 
Rotational Vacuum Concentrator RVC Martin Christ Gefriertrocknungsanlagen 
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2-18 GmbH, Osterode am Harz, Germany 
SpectraFluor PlusTM Tecan, Männedorf, Switzerland 
Suprafuge 22 Heraeus Sepatch, Osterode am Harz, 
Germany 
Thermoshake, Laboshake Gerhard Analytical Systems, 
Königswinter, Germany 
Top stage incubator Oko Lab, Ottaviano, Italy 
Ultrasonic cleaner VWR International GmbH, West 
Chester, PA, USA 
Vi-CellTM XR Beckman Coulter, Brea, CA, USA 
Zeiss LSM 510 Meta confocal laser 
scanning microscope  
Zeiss, Oberkochen, Germany 
 
2.2. Methods 
2.2.1. Cell culture solutions and media 
The following solutions and reagents were used for cultivation and maintenance.  
Table 3 Cell culture solutions and media 
PBS (pH 7.4)   
 
PBS + Ca2+/Mg2+ (pH 7.4)   
NaCl 132.2 mM 
 
NaCl 137 mM 
Na2HPO4 10.4 mM 
 
KCl 2.68 mM 
KH2PO4 3.2 mM 
 
Na2HPO4 8.10 mM 
in H2O   
 
KH2PO4 1.47 mM 
 
  
MgCl2 0.25 mM 
 CaCl2  0.5 mM 
  
 
in H2O   
  
   DMEM++   
 
Trypsin/EDTA (T/E)  
DMEM 500 ml 
 
Trypsin 0.5 % 
FCS  10 % 
 
EDTA 0.20 % 
P/S 1 % 
 
in PBS   
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Collagen G     
Collagen G 0.001 %    
in PBS     
 
FCS was inactivated by partially thawing for 30 min at room temperature, totally 
thawing at 37 °C and finally incubating at 56 °C for 30 min. FCS aliquots were stored 
at -20 °C. 
2.2.2. Cell lines, maintenance and passaging 
HUH7 and HepG2 cells were obtained from Japanese Collection of Research 
Bioresources (JCRB) and German Research Centre of Biological Material (DSMZ) 
(ACC180), respectively. Cell line STR profiling was performed. HCC cells were grown 
in DMEM++. HepaRGTM cells were obtained from Life Technologies. Cells were 
plated and maintained in Williams’ medium E supplemented with GlutaMAXTM and 
HepaRG™ Thaw, Plate, & General Purpose Medium Supplement (Thaw, Plate, & 
General Purpose Working Medium) purchased from Life Technologies. For 
metabolism studies, cells were seeded in Thaw, Plate, & General Purpose Working 
Medium, which was replaced by in Williams’ medium E supplemented with 
GlutaMAXTM and HepaRG™ Maintenance/Metabolism Medium Supplement 
(Metabolism Medium) after 24 h. Thereafter medium was renewed every 3 days. 
Experiments were performed after 7 days of cell maintenance in Metabolism Medium. 
Primary human hepatocyte tissue samples (hHep) and annotated data were obtained 
and experimental procedures were performed within the framework of the non-profit 
foundation HTCR, including the informed patient’s consent. For experiments hHep 
were cultivated in DMEM++. All cells were cultured under constant humidity at 37 °C 
and with 5 % CO2 in an incubator. All culture flasks, multiwell-plates and dishes were 
first coated with collagen G before seeding the cells. Cells were routinely tested for 
contamination with mycoplasma using PCR detection kit VenorGeM (Minerva 
Biolabs). 
After reaching confluency, growth medium was removed, cells were washed twice 
with pre-warmed PBS and detached by incubation with pre-warmed T/E for 
approximately 5 min at 37 °C. Digestion was stopped by adding 10 ml growth 
medium, cells were centrifuged (1000 rpm, 5 min), resuspended in medium, counted 
and plated for the respective experiments. All plates and dishes were pre-coated with 
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collagen G for better adhesion and cell function. Cell concentration and viability were 
determined using Vi-CellTM XR cell viability analyzer (Beckman Coulter). 
2.2.3. Freezing and thawing 
For long-term storage, cells were detached, counted and 2x106  HCC cells or 4x106 
HepaRGTM  were resuspended in 1 ml growth medium supplemented with 20 % FCS, 
1 % P/S and 20 % DMSO. Cells were transferred into cryo vials and immediately 
frozen at -20 °C for 24 h, transferred to -80 °C for at least 6 h and finally to liquid 
nitrogen for long-term storage. For thawing, the frozen cells were warmed up in a 
water bath to 37 °C and transferred into 5 ml growth medium. The cells were pelleted 
and the supernatant was discarded to remove DMSO. Subsequently cells were 
resuspended in growth medium and placed into a 25 cm2 culture flask. The following 
day, growth medium was changed and the cells were left to reach confluency. 
2.2.4. Transient transfection with small-interfering RNA (siRNA) 
For silencing experiments, cells were seeded 24 h prior to transfection with siRNA 
using DharmaFECTTM transfection reagents and manufacturer’s protocol 
(DharmaconTM, GE Healthcare). The c-subunit of the V-ATPase (ATP6V0C) was 
silenced using ON-TARGETPlus SMARTpool siRNA (2 µg) and non-targeting siRNA 
(nt siRNA) as a control (DharmaconTM, GE Healthcare). 48 h after transfections cells 
were harvested for the respective assay.  
2.2.5. Electroporation  
Plasmid transfection was performed by electroporation according to manufacturer`s 
instruction using AmaxaTM Cell Line NucleofectorTM Kit T. In brief, cells were 
detached, counted and 2x106 cells were transferred into a tube, centrifuged and the 
supernatant was discarded. The cells were resuspended in 100 µl NucleofectorTM 
solution and 2 µg plasmid were added. The cell suspension was transferred into a 
cuvette and transfected using the T-28 program. The transfected cells were 
transferred into medium and plated for the respective assay. 
2.2.6. CellTiter-Blue® cell viability assay 
The metabolic capacity of cells can be considered as an indicator for their viability. To 
analyze viability, the CellTiter-Blue® cell viability assay (Promega) was employed, 
which uses the indicator dye resazurin.  
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Figure 9 CellTiter-Blue® cell viability assay reaction In viable cells resazurin (left) is reduced to 
resorufin (right), which shows fluorescence at 590 nm. 
 
Therefore 5,000 cells/well were seeded into 96-well plates and allowed to adhere 
overnight. Before stimulation initial metabolic activity was determined and cells were 
treated as indicated for 72 h. 4 h before end of stimulation time CellTiter-Blue® 
Reagent was added and the fluorescence at 590 nm was measured with the 
SpectraFluor PlusTM plate reader. The fluorescence is proportional to the cell number. 
2.2.7. Crystal violet proliferation assay (Clonogenic Assay) 
For the evaluation of long-term effects on proliferation of HUH7 cells, a clonogenic 
assay was performed. HUH7 cells were seeded, left to adhere for 24 h and treated as 
indicated for 24 h. After stimulation time, cells were detached and reseeded at a 
density of 10,000 cells/well on a 6-well plate. After 7 days cells were stained with 1 ml 
0.5 % crystal violet solution for 10 min at room temperature. After removal of the dye 
and five washing steps with distilled water, cells were imaged at 10x magnification. 
Subsequently, 1 ml dissolving buffer/well was added and absorbance at 550 nm was 
measured with the SpectraFluor PlusTM plate reader. 
Table 4 Clonogenic assay solutions 
Crystal violet solution   
 
Dissolving buffer   
Crystal violet 5 % (w/v) 
 
Trisodium citrate 20 mM 
Methanol 20 % 
 
Ethanol 50 % 
in H2O   
 
in H2O  
 
2.2.8. Immune fluorescence staining 
To stain HUH7 cells for confocal microscopy 20,000 cells/well were seeded on 
ibiTreat μ-slide 8-well slides one day prior to treatment as indicated. After treatment, 
cells were washed with PBS, fixed with 3 % Paraformaldehyde (PFA) for 30 min, 
permeabilized with 0.1 % triton-X and unspecific binding was blocked with 2 % BSA. 
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Subsequently, the proteins of interest were bound with specific antibodies for 2 h at 
25 °C or at 4 °C overnight and visualized with fluorescent secondary antibodies for 
45 min at 25 °C. Cholesterol was stained with 50 µg/ml filipin (Sigma Aldrich) for 2 h 
at 25 °C. Nuclei were stained with TO-PRO®3 or Hoechst. Actin was stained with 
rhodamine-phalloidin. Cells were washed and mounted with FluorSaveTM Reagent 
mounting medium and covered with a glass coverslip. Images were taken by confocal 
microscopy. 
Table 5 Primary antibodies for confocal microscopy 
Antigen Company Cat. No. 
LAMP-1 Developmental Studies 
Hybridoma Bank 
H4A3 
LDLR Santa Cruz sc-18823 
 
Table 6 Secondary antibodies and dyes for confocal microscopy 
Antigen Company Cat. No. 
Mouse IgG (AlexaFluor 488 conjugate) Life Technologies A - 11001 
TO-PRO®3 Life Technologies T3605 
Filipin Sigma Aldrich F4767 
di-4-ANEPPDHQ Life Technologies D36802 
Rhodamine-Phalloidin Life Technologies R-415 
DilLDL Life Technologies L3482 
Hoechst 33342 Sigma Aldrich  H6024 
 
2.2.9. Analysis of membrane polarity 
For analysis of membrane polarity, 20,000 cells/well were seeded on ibiTreat μ-slide 
8-well slides 24 h prior to stimulation. The cells were treated as indicated for 24 h. 
Subsequently, medium was exchanged for DMEM without FCS containing 10 µM of 
the dye di-4-ANEPPDHQ for 30 min at 37 °C. Live cell imaging was performed as 
described previously  using a Leica TCS SP 8 SMD confocal microscope with a top 
stage incubator (Oko Lab, Ottaviano, Italy). In brief, the dye intercalates into 
membranes and changes its emission spectrum due to polarity of the environment. 
By calculating the ratio (generalized polarization, GP) of light intensities between the 
channels membrane polarity can be analyzed.  
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Figure 10 Fluorescence properties of di-4-ANEPPDHQ After excitation at 488 nm (blue line), the 
dye fluoresces either with a peak emission around ~560 nm (green line) when residing in less polar 
environment, or at ~620 nm in the rather polar disordered phase (red line). Both wavelength bands 
indicated by the shaded boxes are detected by two channels. Image adapted from Owen et al. (55). 
 
For analysis of the images a macro for ImageJ (ImageJ 1.46r, NIH, USA) based on 
the one provided by Owen et al. (55) was used designed with the kind help of Erwin 
Steiner. Statistical evaluation of GP value distribution was performed with GraphPad 
Prism.  
2.2.10. Fluorescence recovery after photo-bleaching (FRAP) 
24 h prior to treatment as indicated, HUH7 cells were transfected with a plasmid 
coding for farnesylasted GFP (pAcGFP-C1, Clontech). Electroporation using 
Amaxa® Cell Line Nucleofector® Kit T (program T-28) as described in 2.2.5 was 
employed. 40,000 cells per well were subsequently seeded onto ibiTreat μ-slide 8-
well slides and FRAP assay was performed using a Leica TCS SP 8 SMD confocal 
microscope with a top stage incubator (Oko Lab). A defined region of interest was 
bleached with high laser power and recovery of the GFP signal was monitored by 
recording 60 post bleach images every 10 s.  
 
Figure 11 Plasmid vector information for pAcGFP1-F Adapted from manufacturer’s product 
information (Catalog No. 632511 pAcGFP1-F, Clontech, CA, USA). 
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2.2.11. Cholesterol measurement 
Cellular cholesterol levels were measured using the Amplex® Red Cholesterol Assay 
Kit according to manufacturer’s protocol. The assay is based on an enzyme-coupled 
reaction that detects both free cholesterol and esterified cholesterol by generating 
H2O2 that is subsequently detected using 10-acetyl-3,7-dihydroxyphenoxazine 
(Amplex® Red reagent). Therefore, cells were treated as indicated for 48 h, detached 
and either homogenized right away in a lipid extraction solution containing 
chloroform, isopropanol and IGEPAL CA-630 (7:11:0.1) via sonication, or 
homogenization was performed on lysosomes isolated as described previously (56). 
After centrifugation (13,000x g, 10 min) the organic phase was air dried at 50 °C for 
10 min to remove chloroform. Remaining organic solvent was removed by vacuum at 
30 °C for 30 min. Dried lipids were dissolved in 1x assay reaction buffer and mixed 
1:1 with a working solution containing 300 µM Amplex® Red reagent, 2 U/ml 
horseradish peroxidase (HRP), 2 U/ml cholesterol oxidase and in case of total 
cholesterol measurement 0.2 U/ml cholesterol esterase. After incubation for 30 min at 
37 °C fluorescence was measured with the SpectraFluor PlusTM plate reader. 
2.2.12. Cholesteryl ester analysis 
HUH-7 cells were treated as indicated, trypsinized and collected by centrifugation. 
The cell pellet was frozen in liquid nitrogen and stored at -80 °C until use. The pellet 
was resuspended in methanol, chloroform was added and finally PBS. Cells were 
then centrifuged at 4000 rpm for 5 min and lower chloroform phase was collected. 
The chloroform was evaporated for 20 min at 30 °C and dried lipids were dissolved in 
methanol. After centrifugation at 1500 rpm for 5 min, supernatant was diluted with 
methanol, centrifuged again at 1500 rpm for 5 min and analysed by LC-MS/MS, as 
described previously (57). 
2.2.13. Assessment of apoptosis 
Apoptosis was analyzed according to the method described by Nicoletti et al. (58). In 
this assay, the subG1 population, which is characteristic for DNA fragmentation and 
loss of nuclear DNA, is evaluated. For this purpose, cells were detached, washed 
with PBS and resuspended in 100 µl flow cytometry solution, containing propidium 
iodide (PI) and incubated for 30 min at 4 °C. Apoptotic DNA was determined by flow 
cytometry using BD FACS CantoTM II. For data evaluation the flow cytometry analysis 
software FlowJo 7.6 was employed.  
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Table 7 Flow cytometry solution 
Flow cytometry solution  
 
  
Propidium iodide 75 µM 
 
  
Trisodium citrate 0.1 % 
 
  
Triton-X 100 0.1 %   
in PBS     
 
2.2.14. LDLR surface expression 
Cells were treated as indicated for 24 h. After stimulation, growth medium was 
removed and the cells were washed twice with pre-warmed PBS before trypsination, 
washed again with PBS once and incubated with anti-LDLR antibody (sc-18823, 
santa cruz) for 45 min at room temperature. After washing, secondary antibody 
conjugated to AlexaFluor 488 was added for 45 min at room temperature and after 
two additional washing steps, cells were analyzed by flow cytometry with a 
FACSCanto II cytometer. 
2.2.15. Real-time deformability cytometry (RT-DC) 
For RT-DC measurements the experimental setup has been described earlier (59). 
Cells were trypsinzed and resuspended to a final concentration of about 3x106 
cells/ml in 0.5 % methylcellulose solved in PBS. To achieve cell deformation the cell 
suspension was pumped through a microfluidic chip containing a constricted channel 
of 30 µm x 30 µm at flow rates of 0.16 µl/s, 0.24 µl/s and 0.32 µl/s.  
 
Figure 12 Schematic setup of RT-DC assay setup Image adapted from Otto et al. (59). 
As a reference, non-deformed cells were measured outside the channel in the 
reservoir where cell deformation does not take place. Cell size (cross-sectional area) 
and deformation (1 – circularity) was determined in real-time for >3000 cells per 
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experiment at rates of 100 cells/sec. Isoelasticity lines were assessed as reported 
elsewhere (60).  
 
Figure 13 Calculation of relative deformation RD relative deformation, d(treat-chan) deformation of 
the treated samples in the channel, d(treat-res) deformation of the treated samples in the reservoir, 
d(chan) deformation of the control samples in the channel, d(res) deformation of the control samples in 
the reservoir 
 
Statistical analysis was performed by applying linear mixed effects models. 
Therefore, a fixed effects model is extended by a random effect term that can be 
used to account for error induced by the experimental design. The archazolid A 
treatment was considered as a binary fixed effect whereas biological variations 
between experiments were taken as a random effect. We allowed the model to fit 
random intercepts to attribute for variations in the mean values of the control group 
as well as random interslopes to account for variable differences between the control 
and the archazolid A-treated group. p values were calculated by a likelihood ratio 
test.  
2.2.16. Western Blot  
For analysis of protein levels, Western blot analysis was performed. Firstly, in case of 
total cell lysates, the cells were lysed using RIPA lysis buffer and freezing cells at  
-80 °C. In case of subcellular analysis of proteins, cells were fractionated into 
cytosolic, membrane, mitochondrial and nuclei fraction. Therefore, cells were washed 
with PBS, 500 μl of buffer A were added and cells were scraped off plates. 
Subsequently, the lysate was passed through a 25 Ga needle 10x using a 1 ml 
syringe. After incubation on ice for 20 min, the nuclear pellet was centrifuged out at 
720x g for 5 min at 4 °C. The nuclear pellet was washed once with buffer A, 
resuspended in buffer B and sonicated briefly. The remaining supernatant was 
centrifuged at 10,000x g, the pellet represents mitochondrial fraction. The 
superanatant was transferred to ultracentrifugation at 100,000x g for 1 h at 4 °C. The 
resulting pellet displays the membrane fraction, which was washed once with  
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buffer A, then dissolved in buffer B and sonicated briefly. The remaining lysate 
represents the cytosolic fraction. 
After protein isolation, the concentrations were determined as bicinchoninic (BC) 
assay as described previously (61) and measuring the absorbance with SpectraFluor 
PlusTM plate reader. Briefly, 10 µl protein samples were incubated with 200 µl BC 
assay reagent (30 min at 37 °C) and absorbance was measured (550 nm). As protein 
standard a dilution series of bovine serum albumin (BSA) was used and sample 
protein concentration was determined by linear regression. Equal amounts of protein 
were loaded onto sodium dodecyl sulfate (SDS)-gels, utilizing Page RulerTM 
Prestained as a protein ladder indicator. Proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE; 20 min: 100 V, 40 min: 200 V) using 
the Consort Electrophoresis Power Supply E835 and transferred to nitrocellulose 
membranes (Amersham Bioscience) by tank blotting (1.5 h: 100 V, 4 °C). To block 
unspecific antibody binding, membranes were incubated with 5 % blotto for 1 h. 
Primary antibodies were incubated over night at 4 °C and after washing, secondary 
antibodies were incubated for 2 h at room temperature. Antibodies were diluted in  
5 % BSA (Sigma-Aldrich) in TBST. As secondary antibodies were HRP-coupled ECL 
substrate was added and chemiluminescence was detected with ChemiDoc Touch 
Imaging System (Bio-Rad Laboratories GmbH). Quantification of bands was 
accomplished with Image LabTM Software (Bio-Rad Laboratories GmbH). 
Table 8 Buffers for subcellular fractionation 
Buffer A   
 
Buffer B 
 
Sucrose 250 mM 
 
Sucrose 250 mM 
HEPES (pH 7.4) 20 mM 
 
HEPES (pH 7.4) 20 mM 
KCl 10 mM 
 
KCl 10 mM 
MgCl2 1.5 mM 
 
MgCl2 1.5 mM 
EGTA 1 mM 
 
EGTA 1 mM 
EDTA 1 mM EDTA 1 mM 
in H2O   SDS 0.1 % 
added before use:   Glycerol  10 % 
Complete® EDTA free 4 mM  in H2O  
   added before use:  
   Complete® EDTA free 4 mM 
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Table 9 Buffers for western blot  
RIPA lysis buffer   
 
5x sample buffer   
Tris/HCl (pH 7.4) 50 mM 
 
Tris/HCl (pH 6.8) 3.125 M 
NaCl 150 mM 
 
Glycerol 50 % 
Nonidet NP-40 1 % 
 
SDS 5 % 
Sodium deoxycholate 0.25 % 
 
DTT 2 % 
SDS 0.10 % 
 
Pyronin Y 0.025 % 
activated Na3VO4 0.3 mM 
 
in H2O   
NaF 1 mM 
 
  
β-glycerophosphate 3 mM 
 
1x SDS sample buffer 
pyrophosphate 10 mM 
 
5x sample buffer 25 % 
in H2O    
 
in H2O  
added before use: 
  
  
Complete® EDTA free 4 mM 
 
  
PMSF 1 mM   
H2O2 0.5 mM 
 
  
 
Table 10 Polyacrylamide gels and electrophoresis buffer 
Stacking gel    
 
Separation gel 10 / 12 %   
RotiphoreseTM Gel 30 17 % 
 
RotiphoreseTM Gel 30 33 /40 % 
Tris (pH 6.8) 125 mM Tris (pH 8.8) 375 mM 
SDS 0.1 % 
 
SDS 0.1 % 
TEMED 0.2 % TEMED 0.1 % 
APS 0.1 %  APS 0.05 % 
in H2O  
 TCE 0.05 % 
   in H2O  
Electrophoresis buffer     
Tris  4.9 mM    
Glycine 38 mM    
SDS 0.1 %    
in H2O  
   
 
  
MATERIALS AND METHODS  37 
Table 11 Tank buffers  
5x tank buffer   1x tank buffer  
Tris base 240 mM  5x tank buffer 20 % 
Glycine 195 mM  Methanol 20 % 
in H2O  
 in H2O  
 
Table 12 ECL solution 
ECL solution    
 
  
Tris (pH 8.5) 100 mM 
 
  
Luminol 2.5 mM 
 
  
p-Coumaric acid 1 mM   
H2O2 17 µM 
   
in H2O  
   
 
Table 13 Primary Antibodies for Western Blot 
Antigen Company Cat. No. 
ERK 1/2 Cell signaling 9102 
pERK 1/2 Thr202/Tyr204 Cell signaling 9106 
GAPDH Santa Cruz sc-69778 
MEK 1/2 Santa Cruz sc-436 
pMEK 1/2 Ser217/221 Cell signaling 9121 
panRas Santa Cruz sc-14022 
Raf 1 Santa Cruz sc-7267 
pRaf-1 Ser 338 / Tyr 341 Santa Cruz sc-28005-R 
PI3K Upstate 06-195 
Akt Cell Signaling 9272 
pAkt (Ser473) Santa Cruz sc-7985-R 
Bad Cell signaling 9292 
pBad (Ser136) Cell siganling 9295 
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Table 14 Secondary Antibodies for Western Blot 
Antigen Company Cat. No. 
Mouse IgG (HRP conjugate) Santa Cruz sc-2005 
Rabbit IgG (HRP conjugate) Bio-Rad 172-1019 
 
2.2.17. Ras activity assay 
Ras activation status of the cells was determined using the Ras Assay Kit, according 
to manufacturer’s protocol. Cells were seeded 24 h prior to treatment with archazolid 
(2.5/10 nM, 48 h) and cholesterol (10 µg/ml, 48 h). After stimulation, medium was 
aspirated off, ice-cold lysis solution, containing GST-Raf-RBD which specifically 
binds to active GTP-bound Ras, was added and cells were scraped off, using a 
rubber police man. After centrifugation (12,000x g, 4 °C), supernatant was mixed with 
Glutathione-Sepharose-Slurry beads, that bind to GST-Raf-RBD and incubated under 
constant mixing for 30 min at 4 °C. After incubation, beads were spinned down and 
drained well, mixed with SDS-containing sample buffer for SDS-PAGE, denatured for 
10 min at 95 °C and subjected to Western Blot as described in paragraph 2.2.16. 
Protein loading on the gel was determined using 0.5 % trichloroethanol (Sigma) 
polyacrylamide gels as described before (62). Primary antibody detecting panRas 
was provided in the kit and secondary antibody goat-anti-mouse IgG conjugated to 
HRP were used (Santa Cruz). 
2.2.18. Quantitative real-time PCR (qPCR) 
Cells were treated as indicated and total mRNA was isolated using the Qiagen 
RNeasy Mini Kit according to manufacturer’s protocol. The concentration of isolated 
messenger RNA (mRNA) was determined using the NanoDrop® ND-1000 
spectrophotometer analyzing the absorption at 260 nm (A260) and 280 nm (A280). 
The obtained RNA was re-transcribed using the High Capacity cDNA Reverse 
Transcription Kit according to manufacturer’s instructions. Obtained complementary 
DNA (cDNA) was stored at 4 °C until quantitative real-time Polymerase Chain 
Reaction (qPCR). The SYBR Green Master Mix was used with the respective 
primers. Actin served as housekeeping gene. qPCR was performed with the 
QuantStudio® 3 Real-Time Instrument. Average CT values of target genes were 
normalized to control as ΔCT. Changes in mRNA expression levels were shown as 
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fold expression (2-ΔΔ CT) calculated by the ΔΔCT method normalized to housekeeping 
gene as described previously (63).  
Table 15 Primer sequences used for qPCR 
target mRNA  forward sequence reverse sequence 
actin  
5’ CCA ACC GCG AGA AGA 
TGA 3’ 
5’ CCA GAG GCG TAC 
AGG GAT AG 3’ 
LDL-R 
5’ CTA CAA GTG GGT CTG 
CGA TG 3’ 
5’ TTT GCA GGT GAC AGA 
CAA GC 3’ 
LX-R 
5’ TTC ACC TAC AGC AAG 
GAC GA 3’ 
5’GAA CTC GAA GAT GGG 
GTT GA 3’ 
HMGCR 
5’ GTC ATT CCA GCC AAG 
GTT GT 3’ 
5’ GGG ACC ACT TGC TTC 
CAT TA 3’ 
SREBP-2 
5’ ACA AGT CTG GCG TTC 
TGA GG 3’ 
5’ ACC AGA CTG CCT AGG 
TCG AT 3’ 
 
2.2.19. In vivo HUH-7 xenograft mouse model 
Thirty-two female SCID mice (Charles River „CB17/lcr-PrkdcSCID/lcrlcocrl”) were 
locally shaved and 3x106 HUH-7 cells were injected subcutaneously into the flank of 
each mouse. Mice were divided into four groups and treated intraperitoneally with  
0.2 mg/kg archazolid, 10 mg/kg simvastatin, 0.2 mg/kg archazolid in combination with 
10 mg/kg simvastatin in 5 % DMSO / 10 % solutol / PBS or equal amounts of 5 % 
DMSO / 10 % solutol / PBS. Mice were treated daily. Measurement of tumors was 
done every 2 to 3 days with a caliper, using the formula a x b2/2. The average tumor 
volumes of the two groups were compared over time. In vivo experiments were 
executed by Melanie Ulrich and Kerstin Loske (Group of Prof. Dr. Angelika M. 
Vollmar, University of Munich, Pharmaceutical Biology). Animal experiments were 
approved by the District Government of Upper Bavaria in accordance with the 
German animal welfare and institutional guidelines. 
2.2.20. Immune histochemistry (IHC) 
IHC analysis of tumor tissue sections was performed as described previously [49] 
using anti-LAMP1-antibody (Abcam), filipin (Sigma Aldrich), anti-Ki67-antibody and 
haematoxylin (Sigma Aldrich).  
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For Ki67 staining, paraffin embedded tumor sections were de-paraffinated by 
incubation in xylol, followed by ethanol 100 %, ethanol 95 % and water. For antigen 
retrival, tissue sections were incubated in sodium citrate buffer at 95 °C for 20 min. 
After cooling, sections were washed two times with 0.05 % triton-X in PBS, 
peroxidase activity was quenched with 7.5 % H2O2 in water for 10 min at room 
temperature and unspecific binding was blocked with blocking serum of the 
VECTASTAIN Elite ABC HRP Kit for 20 min at room temperature. Sections were 
incubated with anti-Ki67-antibody (ab-15580, abcam) for 1 h at room temperature, 
washed twice with PBS, incubated with secondary antibodies and universal reagent 
of the VECTASTAIN Elite ABC HRP Kit. After washing, AEC substrate from the 
ImmPACT AEC Peroxidase (HRP) Substrate kit was added for 30 min. After 
additional washing, haematoxilin counterstaining was performed, sections were 
washed and mounted in FluorSafeTM and sealed with cover slides. Ki67 staining was 
evaluated using the Olympus BX41 microscope. 
For LAMP-1 and cholesterol staining the same procedure was used, however, 
secondary antibody mouse IgG (AlexaFluor 488 conjugate) and filipin were added in 
blocking solution of the VECTASTAIN elite ABC HRP Kit for 2 h at room temperature. 
Cholesterol and LAMP-1 staining were evaluated by confocal microscopy using a 
Leica TCS SP 8 SMD confocal microscope.  
Table 16 Buffer for IHC 
Sodium citrate buffer    
 
  
Tri-Na-Citrate(dihydrate)  10 mM 
 
  
Tween  0.5 % 
 
  
HCl ad pH 6.0    
in H2O     
 
2.2.21. Statistical Analysis 
All experiments were performed at least three times unless stated otherwise. 
Statistical analysis was performed using GraphPad Prism® (GraphPad Software, 
Inc., La Jolla, CA, USA). Graph data represent means ± SEM. One-way 
ANOVA/Dunnett´s multiple comparison test and individual unpaired t-tests were 
conducted. p values less than 0.05 were considered significant. 
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3. RESULTS 
3.1. V-ATPase inhibition induces cancer cell stiffening and alters 
membrane fluidity in HCC 
3.1.1. Real-time deformability cytometry reveals cancer cell stiffening due to 
V-ATPase inhibition 
Biophysical characteristics of cancer cells have come into focus lately, regarding the 
search for new therapy options. In this context, it has been reported that increased 
softness of cancer cells correlates with malignancy (46). Interestingly, the  
V-ATPase has been reported to regulate cholesterol metabolism (10,11,23), a fact 
which lead to the working hypothesis that inhibition of V-ATPase by archazolid A 
might influence cancer cell biophysical properties. To elucidate this hypothesis, we 
utilized a relatively new method to analyze the deformation of cells, the real-time 
deformability cytometry (RT-DC) in collaboration with Dr. Maria Winzi (Group of Prof. 
Dr. Jochen Guck, Biotec, TU Dresden). RT-DC is a microfluidic-based technique 
which allows the measurement of cell deformation while cells pass through a narrow 
constriction with a rate of 100 cells/s (59). 
We analyzed the influence of archazolid A treatment on the deformability of HUH-7 
cancer cells and the non-malignant hepatocyte-like cell line HepaRG. Firstly, we 
assessed the influence of the applied flow rates on the deformation, as they correlate 
with shear force subjected to the cells. We found that at all applied flow rates, HUH-7 
cells behaved similarly (Fig 14 A). In general, we could show that HUH-7 control cells 
change their shape to a rather oval structure, whereas treated HUH-7 cells remain 
quite spherical (Fig 14 C). Secondly, we also monitored the behavior of HepaRG 
cells at different flow rates and revealed that also for the non-malignant cells, effects 
are independently of the force applied (Fig 14 B). To exclude that cellular shape is 
altered directly by stimulation, cells were imaged in the reservoir before entering the 
channel, however, no difference was detected (Fig 14 A, B). Taken together, the RT-
DC measurements clearly showed that treatment reduces overall deformability of 
HUH-7 cells (Fig 14 D), whereas deformability of HepaRG remained unaffected (Fig 
14 E), indicating a cancer cell selectivity of the effect. 
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Figure 14 V-ATPase inhibition selectively reduces deformability of cancer cells in RT-DC 
measurements HUH-7 (A) and HepaRG (B) cells were left untreated (blue) or were treated with 
archazolid A (10 nM, 24 h) (red) and subjected to flow rates of 0.16 µl/s, 0.24 µl/s or 0.32 µl/s or no 
shear stress (reservoir). Blots show contours of dot blots of deformation compared to cell size. (C) 
Representative images of an HUH-7 control cell (upper image) and an archazolid A (10 nM, 24 h) 
treated cell (lower image) when subjected to shear force in the flow channel (0.24 µl/s). Red line 
indicates outline for calculation of deformation. (D, E) Representative dot blots of deformation 
compared to cell size at a flow rate of 0.16 µl/s for HUH-7 and HepaRG, respectively. Blue dots 
represent control cells, red dots represent archazolid A treatment (10 nM, 24 h). Graphs represent cell 
size (cross sectional area) versus deformation (1-circularity) with isoelasticity lines representing areas 
of identical stiffness. p*< 0.01, p-values of three independent experiments with > 3000 cells per 
experiment were determined by a likelihood ratio test. 
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3.1.2. V-ATPase inhibition induced cell stiffening due to alterations in 
membrane properties 
The stiffness of cells in general is mainly influenced by two factors: the cytoskeleton 
and the membrane. As we could detect no evident differences in actin cytoskeleton of 
HUH-7 cells (Fig 15), we focused on possible effects of archazolid A treatment on the 
membrane.  
 
Figure 15 V-ATPase inhibition shows no evident influence on actin cytoskeleton HUH-7 cells 
were treated with archazolid A as indicated (24 h) stained for actin (red) and nuclei (blue) and 
analyzed by confocal microscopy. Representative images out of three independent experiments are 
shown. Scale bar 25 µm. 
 
For this purpose, we analyzed plasma membrane fluidity, using a fluorescence-
recovery after photo-bleaching (FRAP) approach on cells transfected with a 
membrane-targeted (i.e. farnesylated) GFP coding plasmid. After bleaching 
fluorescence in a specific membrane area, recovery was monitored over time and the 
speed constant was calculated as described in the methods section (2.2.10). In 
control cells, the bleached area was repaired relatively fast, whereas in archazolid A 
treated cells the restoration of fluorescence was hindered (Fig 16 A). Hence, the 
recovery constant was significantly slower in treated cells compared to control cells 
(Fig 16 B). This finding indicates reduced lateral mobility of farnesylated proteins in 
the plasma membrane of archazolid A treated cells.  
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Figure 16 V-ATPase inhibition causes alterations in membrane fluidity (A, B) FRAP of HUH-7 
cells transfected with membrane targeted (farnesylated) GFP and treated with archazolid A (10 nM, 
24 h) was analyzed by confocal microscopy. Recovery speed constant K was calculated by non-linear 
curve fit. One representative image and diagram of FRAP recovery of three independent experiments 
are shown. Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, 
Dunnett post test 
The plasma membrane of mammalian cells is composed of a variety of different lipids 
and proteins, which influence membrane biophysical properties, localization of 
signaling molecules and fluidity (64). In order to investigate the cause of the reduced 
lateral mobility of farnesylated proteins, we investigated specifically polarity of the 
membrane. Therefore, we used the membrane-intercalating, polarity sensitive dye  
di-4-ANEPPDHQ. This dye undergoes a 60 nm spectral blue shift between 
disordered and ordered membrane compartments, representing non-raft and 
cholesterol-rich lipid-raft membrane regions, respectively. These special fluorescent 
properties of  
di-4-ANEPPDHQ allow a quantitative analysis of membrane polarity, by calculating a 
value for generalized polarization (GP), as described previously (65).  
Treatment with archazolid A resulted in a drop of GP values, indicating an increase in 
membrane polarity in HUH-7 and HepG2 cells. In contrast, the non-malignant 
HepaRG cells and primary human hepatocytes (hHep) showed no change in 
membrane polarity following treatment. (Fig 17 A). For easy visualization, heat map 
images (Fig. 17 C) and GP value distribution histograms (Fig. 17 D) were compiled. 
To exclude responsibility of an off-target event for increased membrane polarity, we 
performed siRNA mediated knock-down of the V-ATPase and subsequently 
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measured GP values. Knocking-down V-ATPase also reduced GP values, confirming 
V-ATPase dependency of the mechanism (Fig 17 B). These results clearly depict the 
ability of archazolid A to alter biophysical characteristics selectively in cancer cells, 
while leaving non-malignant cells unaffected.  
 
Figure 17 V-ATPase inhibition leads to an alteration in plasma membrane composition  
(A) HUH-7, HepG2, HepaRG and hHep were treated with archaolid A as indicated (2.5/10 nM, 24 h) 
and (B) HUH-7 cells were transiently transfected with nt siRNA or siRNA silencing c-subunit of the V-
ATPase (ATP6V0C siRNA) (72 h). Membrane polarity was analyzed by confocal microscopy of live 
cells stained with di-4-ANEPPDHQ. Representative heat map images (C) and histogram (D) of 
generalized polarization (GP) value distribution of HUH-7 di-4-ANEPPDHQ stainings are shown. A GP 
value drop indicates increased membrane polarity. Bars are the mean ± SEM of three independent 
experiments. p*<0.05 One-way ANOVA, Dunnett post test (A) or unpaired t-test (B) 
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3.2. V-ATPase inhibition alters cholesterol metabolism of HCC 
cells 
We could show that archazolid A alters plasma membrane properties of cancer cells. 
The plasma membrane of eukaryotic cells is composed of phospholipids, 
sphingolipids and the rather unpolar sterol cholesterol (66). In order to determine the 
cause for reduced fluidity and increased membrane polarity, we focused on analyzing 
membrane components. 
3.2.1. Availability of free cholesterol is diminished upon V-ATPase inhibition 
We focused on cholesterol metabolism, as it has been reported recently to be 
influenced by the V-ATPase (10). Employing the enzyme-based Amplex Red® 
cholesterol measurement kit, we evaluated levels of both, total and free cholesterol. 
The assay revealed, that treatment with archazolid A led to a reduction in the 
proportion of free cholesterol in HCC cell lines, yet leaving non-malignant cells 
unaffected (Fig 18 A). In HUH-7 cells, knock-down of the V-ATPase also reduced the 
proportion of free cholesterol within the cell, ensuring a V-ATPase dependent 
mechanism (Fig 18 B). 
Additionally, we conducted ultraperformance liquid chromatography-coupled ESI 
tandem mass spectrometry (UPLC-MS/MS) measurements in cooperation with Dr. 
Andreas Koeberle (Group of Prof. Oliver Werz, Institute of Pharmacy, Friedrich 
Schiller University Jena). UPLC-MS/MS analysis of cholesteryl-ester (CE) species in 
archazolid A treated HUH-7 cells showed, that while the overall amount of CE within 
the cells is not altered (Fig 18 C), the composition of CE changes upon V-ATPase 
inhibition (Fig 18 D). These data point to a role of V-ATPase in the availability of free 
cholesterol and CE composition. 
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Figure 18 V-ATPase inhibition reduces free cholesterol levels and alters cholesteryl-ester 
composition (A) Ratio of levels of free to total cholesterol of HUH-7, HepG2, HepaRG and hHep cells 
treated with archazolid A (2.5/10 nM, 48 h) assessed by Amplex Red® assay. (B) HUH-7 cells were 
transiently transfected with nt siRNA or siRNA silencing c-subunit of the V-ATPase (ATP6V0C siRNA) 
(72 h) and cholesterol content was analyzed. (C, D) HUH-7 cells were treated with archazolid A 
(2.5/10 nM, 48 h), lipids were extracted and CE composition was analyzed by mass spectrometry. 
Bars are the mean ± SEM of three independent experiments. p*<0.05 One-way ANOVA, Dunnett post 
test (A, C, D) or unpaired t-test (B) 
3.2.2. V-ATPase inhibition impedes internalization of LDL via the LDLR and 
enhances LDLR expression 
Free cholesterol availability in mammalian cells is dependent on supply by de novo 
synthesis or by uptake of cholesterol as main component of low-density lipoprotein 
(LDL) via its respective receptor (LDLR), however uptake by internalization is the 
primary cholesterol source. In previous studies of our group, we showed an inhibition 
of EGF and transferrin receptor recycling by archazolid (11,23), hence we 
hypothesized a similar fate for the LDLR. 
Therefore, we analyzed the presence of the LDLR on the surface of HUH-7 cells. 
Flow cytometry with labelled antibody conjugates revealed an increased amount of 
the LDLR on the surface of archazolid A treated HUH-7 cells (Fig 19 A). Enhanced 
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surface appearance can be caused by several ways in principle, on the one hand by 
increased expression of the protein and on the other hand by reduced internalization. 
In order to investigate the underlying mechanism we analyzed LDLR expression level 
upon archazolid A treatment by quantitative real-time PCR (qPCR). The experiment 
revealed increased expression of the receptor on mRNA level upon inhibition of the 
V-ATPase (Fig 19 B).  
So as to investigate the effect of archazolid A on LDLR internalization, we used two 
different strategies. Firstly, we performed an LDLR internalization assay with a 
fluorescently labelled antibody conjugate (Fig 19 C). After internalization, LDLR 
distribution within the cell was visualized by confocal microscopy. In control cells, 
LDLR is properly internalized, leading to intracellular bright green dots in the confocal 
image (Fig 19 C, upper lane). Following archazolid A treatment, the green signal 
disappears leaving only diffuse membrane staining (Fig 19 C, lower lane), pointing to 
a reduction in internalization. In a second approach, we used a labelled LDL 
conjugate (Fig 19 D). In a similar internalization assay, we could show that LDL is 
properly internalized in control cells (Fig 19 D, upper lane), but internalization is 
diminished by archazolid A treatment, leading to accumulation of LDL at the outer 
boarder of the cells (Fig 19 D, lower panel). 
Taken together, these findings clearly show that treatment with archazolid A leads to 
increased LDLR transcription and a decreased LDLR internalization, followed by a 
decreased uptake of LDL together with an increased presence of LDLR on the 
cellular surface, thereby most likely disturbing cholesterol metabolism. 
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Figure 19 LDLR internalization and LDL uptake is inhibited by archazolid A treatment (A) LDLR 
surface expression of HUH-7 cells was visualized by antibody staining and analyzed by flow cytometry 
after archazolid A treatment (2.5/10 nM, 24 h). (B) Relative mRNA expression levels of LDLR in  
HUH-7 cells were detected with the AB 7300 RealTime PCR system. Bars are the mean ± SEM of 
three independent experiments. p*<0.05 Repeated measures ANOVA, Dunnett post test (C) HUH-7 
cells were treated with archazolid A (2.5/10 nM, 24 h) and subsequently starved for 2 h. After 
incubation with PMA (1 h) internalized LDLR was visualized by antibody staining and analyzed by 
confocal microscopy. (D) HUH-7 cells were treated with archazolid A (2.5/10 nM, 24 h) and 
subsequently starved for 1.5 h. Internalization of DilLDL (fluorescently labeled soluble LDL) was 
analyzed by confocal microscopy. Representative images out of three independent experiments are 
shown. Scale bar 25 µm (left columns) and 5 µm (right columns), respectively. 
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3.2.3. V-ATPase inhibition leads to cholesterol trapping and induction of de 
novo synthesis 
In summary, our previous data show a restriction of free cholesterol, plasma 
membrane cholesterol depletion and a reduction of LDL uptake, however, the 
question where the free cholesterol is located still remained. In order to clarify this 
issue, we investigated subcellular localization of cholesterol. As free cholesterol is 
mainly released from lysosomes under normal conditions and lysosomes greatly 
depend on a functional V-ATPase, we assumed lysosomes as location for the 
restricted cholesterol in archazolid A treated cells.  
We hence isolated lysosomes from treated cells as described previously (56), and 
measured cholesterol levels employing the Amplex Red® cholesterol measurement 
kit. The analysis showed, that the amount of cholesterol in purified lysosomes 
drastically increases due to archazolid A treatment (Fig 20 A). This finding could 
further be supported by a confocal staining for cholesterol and the lysosomal marker 
protein LAMP-1. Control cells displayed a fine dispersion of LAMP-1 and cholesterol 
within the cell, whereas archazolid A treated cells showed huge accumulations of 
colocalized stainings (Fig 20 B), indicating a cholesterol trapping within the 
lysosomes of treated cells.  
Since archazolid A treated cells obviously suffer from cholesterol depletion, due to 
trapping in the lysosomes and impaired uptake, we supposed that the cells might 
upregulate de novo cholesterol synthesis. We therefore investigated the impact on 
cholesterol regulating genes SREBP-2 and HMGCR of archazolid A single treatment 
and combination treatment of archazolid A with the cholesterol synthesis inhibitor 
simvastatin to block possibly increased synthesis. qPCR analysis showed, that cells 
indeed upregulate the expression of SREBP-2 (Fig 20 C), the master regulator of 
cholesterol synthesis and also the expression of HMGCR (Fig 20 D). HMGCR is the 
direct target of simvastatin and catalyzes the reduction of HMG-CoA to mevalonate, 
the rate-limiting step of cholesterol synthesis. As expected, combination therapy 
further enhanced archazolid A induced upregulation of transcription, indicating a 
feedback regulation, due to cholesterol depletion. 
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Figure 20 Lysosomal cholesterol trapping and induction of de novo cholesterol synthesis due 
to archazolid A treatment (A) HUH-7 cells were treated with archazolid A as indicated (2.5/10 nM,  
48 h) and lysosomes were isolated. Levels of total cholesterol in lysosomes were analyzed by 
AmplexRed® assay. (B) HUH-7 cells were treated as indicated (2.5/10 nM, 24 h), stained for 
cholesterol (red), lysosomes (green) and nuclei (blue) and analyzed by confocal microscopy. 
Representative images out of three independent experiments are shown. Scale bar 20 µm. (C, D) 
HUH-7 cells were treated as indicated with archazolid A, simvastatin or a combination of both 
compounds as indicated for 24 h. Relative mRNA expression levels of SREBP-2 and HMGCR 
respectively, were detected with the AB 7300 RealTime PCR system. Bars are the mean ± SEM of 
three independent experiments. p*<0.05 Repeated measures ANOVA, Dunnett post test 
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3.3. Plasma membrane cholesterol depletion leads to impaired 
Ras signaling 
3.3.1. Activation of the small GTPase Ras is impaired upon V-ATPase 
inhibition 
As cholesterol homeostasis is disrupted due to lysosomal trapping leading to plasma 
membrane cholesterol depletion, we were interested in possible functional 
consequences. Cholesterol-rich lipid-rafts are particularly important signaling 
platforms for the activation of farnesylated proteins (52), so we investigated the 
impact of archazolid A treatment on the small GTPase Ras. First of all, we checked 
for changes in the overall protein level of Ras, yet could not determine any changes 
following treatment (Fig 21 A). In a second approach, we performed a subcellular 
fractionation to obtain the membrane fraction of the cells, in which we quantified Ras 
protein expression. We could observe a significant reduction of Ras protein levels 
within membrane fractions (Fig 21 B) and furthermore, confocal staining of Ras 
showed that while the signal is finely dispersed over the whole cell in control cells, 
the Ras staining is restricted to few accumulations in archazolid A treated cells (Fig 
21 C). These findings point to a mislocalized Ras protein, leading to the assumption 
that Ras activation might be hindered.  
To test this hypothesis, we precipitated active Ras in whole cell lysates of treated and 
control cells and found that the amount is decreased upon archazolid A treatment 
(Fig 21 D). To proof that inhibition of Ras activation is cancer cell specific, we 
induced Ras signaling in the non-malignant HepaRG cells by EGF treatment and 
then observed the effect of archazolid A on active Ras. The fact that we could not 
observe changes in active Ras levels in HepaRG cells (Fig 21 E) indeed points to a 
tumor specific effect. To verify plasma membrane cholesterol depletion as underlying 
mechanism of decreased Ras activation, we added soluble cholesterol to the medium 
of treated cells and quantified Ras activation. Ras remained active despite  
archazolid A treatment when medium was supplemented with cholesterol (Fig. 21 F) 
confirming a cholesterol dependency. 
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Figure 21 Archazolid A reduces Ras activation in a cholesterol-dependent manner (A) PanRas 
protein expression of HUH-7 cells was detected by western blot (WB) upon archazolid A treatment  
(48 h). (B) PanRas protein level in membrane fractions of archazolid A (48 h) treated HUH-7 was 
detected by WB. (C) HUH-7 cells were treated as indicated (2.5/10 nM, 24 h), stained for cholesterol 
(blue), panRas (green) and nuclei (red) and analyzed by confocal microscopy. White arrow heads 
show Ras accumulations. Representative images out of three independent experiments are shown. 
Scale bar 20 µm. (D, E) Active Ras was precipitated in cell lysates of archazolid A treated (48 h)  
HUH-7 and HepaRG cell lysates and analyzed by WB, respectively. In HepaRG cells Ras signaling 
was stimulated by EGF (100 ng/ml) treatment 15 min prior to lysis. (F) HUH-7 cells were treated with 
archazolid A together with or without cholesterol as indicated (48 h). Active Ras was precipitated in 
cell lysates and detected by WB. Bars are the mean ± SEM of three independent experiments. 
p*<0.05 One-way ANOVA, Dunnett post test 
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3.3.2. Ras downstream signaling is altered upon treatment 
Signaling of the small GTPase Ras is of crucial importance for various downstream 
signaling pathways within the cell. Most prominent are the MAPK pathway and the 
PI3K/Akt pathway (52). In order to examine possible effects on downstream 
signaling, we performed western blot experiment on various different downstream 
regulators.  
Our data show that the activating phosphorylation of Raf-1, MEK 1/2 and ERK 1/2 is 
reduced upon archazolid A treatment (Fig 22 A), indicating an inhibition of the MAPK 
pathway, whereas PI3K/Akt remains unaffected (Fig 22 B). To compensate a 
possible escape mechanism by increased cholesterol synthesis, we additionally 
treated cells with simvastatin. Simvastatin treatment alone did not affect MAPK or 
PI3K/Akt signaling and combination therapy showed similar effects as archazolid A 
single treatment (Fig 22 A, B). 
In these experiments we could show that archazolid A reduces MAPK signaling 
downstream of Ras activation.  
 
Figure 22 Effect of archazolid A on Ras downstream signaling Protein expression of Raf-1,  
pRaf-1 (Ser338/Tyr341), MEK 1/2, pMEK 1/2 (Ser217/221), ERK 1/2 and pERK 1/2 (Thr202/Tyr204) 
(A) or PI3K, Akt, pAkt (Ser473), Bad and pBad (Ser136) (B) of HUH-7 cells treated with archazolid A, 
simvastatin or combination (48 h) was analyzed by WB. GAPDH served as loading control. 
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3.4. A combination therapy approach to inhibit HCC proliferation 
3.4.1. A combination of archazolid and simvastatin leads to synergistic 
growth inhibition of HCC cells in vitro 
We showed that archazolid A is able to restrict cholesterol access and to cause 
inhibition in MAPK signaling due to cholesterol depletion in a Ras dependent manner. 
As Ras signaling is essential for cancer cell proliferation we investigated the influence 
of archazolid A in a CellTiter Blue proliferation assay. Treatment of the cancer cell 
lines HUH-7 and HepG2 resulted in a strong, concentration dependent inhibition of 
proliferation, while HepaRG cells remained unaffected (Fig 23 A) supporting the 
previously detected cancer cell specificity.  
As we had observed an upregulation of cholesterol synthesis regulating genes 
SREBP-2 and HMGCR (see Fig 20 C, D), we assumed that a combination therapy of 
archazolid A with the HMGCR inhibitor simvastatin might be beneficial for treatment, 
despite the fact that simvastatin treatment did not significantly affect Ras downstream 
signaling (see Fig 21 A, B). Firstly, we analyzed the ability of simvastatin single 
treatment on the proliferation of HCC cells. A CellTiter Blue assay revealed that 
simvastatin single treatment concentration dependently reduced the ability of HCC 
cells to proliferate (Fig 23 B). In a second approach we investigated the beneficial 
effect on proliferation of a combination therapy with both drugs. We could show that 
the combination therapy synergistically inhibits proliferation of HUH-7 and HepG2 
cells in vitro (Fig 23 C). 
The MAPK pathway is known to be important in the regulation of proliferation. 
However, induction of apoptosis might also be responsible for the reduced viability of 
HCC cells in the CTB assay. To address this question, we determined apoptosis and 
found that apoptosis is almost at control level in single treatment and only mildly 
increased in combination therapy (Fig 23 D), indicating inhibition of proliferation as 
main mechanism of action. In addition, we could show that combination therapy also 
has a long-term inhibiting effect on proliferation, as determined by clonogenic survival 
assay (Fig 23 E).  
In conclusion, our data show a strong anti-proliferative effect of archazolid A on HCC 
cells and a clearly beneficial effect of combining archazolid A with simvastatin in vitro. 
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Figure 23 Combination therapy with archazolid A and simvastatin shows strong anti-
proliferative effects (A) Proliferation of HUH-7, HepG2 and HepaRG cells was analyzed in a CellTiter 
Blue assay, after treatment as indicated with archazolid A (72 h). (B, C) Proliferation of HUH-7 and 
HepG2 was analyzed in a CellTiter Blue assay after treatment with simvastatin or combination therapy 
as indicated (72 h), respectively. (D) Apoptotic cell death of HUH-7 and HepG2 cells treated as 
indicated (48 h) was analyzed by PI staining and subsequent flow cytometry. (E) HUH-7 cells were 
pre-treated as indicated for 24 h and subjected to clonogenic survival for 7 d. Colonies were stained 
with crystal violet and imaged at 10x magnification. Crystal violet was re-dissolved and staining was 
assessed by measurement of absorption. Bars are the mean ± SEM of quantification of three 
independent experiments. p*<0.05 One-way ANOVA, Dunnett post test 
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3.4.2. Archazolid strongly inhibits tumor growth in an in vivo mouse 
xenograft model  
Following the quite promising effects of a combination therapy on in vitro proliferation, 
we performed a HUH-7 mouse xenograft model. Importantly, daily treatment of mice 
bearing solid tumors with archazolid for 10 days resulted in a significant decrease in 
tumor size at study endpoint (Fig 24 A, red bar). Also the respective growth rate of 
tumors in archazolid treated mice was significantly slower than in control group (Fig 
24 B, red curve). Surprisingly, treatment of mice with simvastatin lead to slightly 
increased tumor volume at study end point (Fig 24 A, yellow bar) and an increased 
proliferation rate (Fig 24 B, yellow curve). This resulted in a tumor volume 
comparable to control cells, and only a slightly reduced proliferation rate of tumors in 
animals treated with a combination therapy (Fig A and B, orange bar and curve).  
Since the liver is the primary organ in regulating cholesterol homeostasis in vivo, 
livers were dissected at study endpoint to check for obvious side effects of treatment. 
Visual examination of the livers showed no obvious signs for severe side effects like 
e.g. fatty livers (Fig 24 C).  
Consistent with the reduction in proliferation rate and reduced tumor volume upon 
archazolid treatment, expression of the proliferation marker Ki67 was significantly 
reduced in tissue samples of tumor sections (Fig 24 D). Furthermore, staining of 
tumor sections for cholesterol and lysosomes revealed lysosomal accumulation as 
expected by our in vitro data.  
Taken together, we could show that archazolid strongly inhibits proliferation of HCC 
cells in vitro and in vivo by cholesterol restriction to the lysosomes. However, a 
combination therapy of archazolid and simvastatin in vivo needs further evaluation.  
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Figure 24 Archazolid leads to reduced proliferation in vivo (A, B) HUH-7 cells were injected s.c. 
into the flanks of 32 SCID mice. Mice were divided in four groups and treated daily i.p. with archazolid, 
simvastatin, a combination thereof or equal amounts of solvent. Tumor volume (A) and growth rates α 
(B) (Co α = 1.374 mm
3
/ h, archazolid α =0.733 mm
3
/ h, simvastatin α =1.687 mm
3
/ h, combination α 
=1.119 mm
3
/ h) are indicated. (C) At study end point mice were sacrificed and livers were dissected for 
visual examination. (D) Paraffin sections of tumors were stained for Ki67 and nuclei. (E) Paraffin 
sections of tumors were stained for cholesterol (blue) and LAMP-1 (green). Representative images of 
control and archazolid treated mice are shown. Scale bar 20 µm. Bars are the mean ± SEM of three 
independent experiments. p*<0.05 One-way ANOVA, Dunnett post test (A, B) or unpaired t-test (D), 
respectively 
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4. DISCUSSION 
This work reveals that the V-ATPase inhibitor archazolid reduces tumor cell 
proliferation in vitro and in vivo by modifying the mechanical phenotype of HCC cells 
through lysosomal cholesterol trapping, while leaving non-malignant cells unaffected. 
In an interdisciplinary approach using biophysical and cell-biological methods we 
were able to identify a new option for the treatment of HCC. Furthermore, we found 
evidence, that a combination therapy of V-ATPase inhibition with cholesterol 
synthesis inhibitors might be beneficial.  
4.1. The V-ATPase influences membrane properties of the cell - 
and vice versa? 
In the recent past, research mainly focused on directly influencing signaling pathways 
in order to affect proliferation, invasion and metastasis of cancer cells. Lately 
however, evidence accumulates that these processes greatly depend on the 
biomechanical and biophysical aspects of the cells and their environment (67), which 
opens new possibilities in cancer treatment.  
In our study, we show that the HCC cell line HUH-7 is more deformable than the non-
malignant hepatocyte cell line HepaRG, indicating increased compliance as a 
characteristic of liver cancer. These data are in line with the findings of Zhang et al., 
which reveal differences in elastic coefficients of HCC cells compared to non-
malignant tissue and connect them to tumor cell invasion and metastasis (68). 
Indeed, several studies now exist, which analyzed differences in mechanical 
phenotype of cancer cells in comparison to their non-malignant counterparts. Along 
this line, Lin et al. found that different cell lines of breast, bladder, cervical and 
pancreatic cancer show increased softness when compared to their respective, non-
malignant counter-parts. Furthermore, they correlated increased migratory and 
invasive capability with a loss of sensing and adaption to stiffness changes of the 
extracellular environment (46). Another study showed a correlation of the softness of 
tumor cell lines and patient cancer cells with invasiveness and even postulates the 
use of the mechanical phenotype for grading (69). Moreover, our data show that 
pharmacological V-ATPase inhibition in HCC cell lines increased cell stiffness 
compared to untreated cells, while leaving non-malignant cells unaffected, thereby 
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opening a new possibility for the treatment of HCC by specifically addressing 
biomechanical properties of liver cancer cells. 
We could demonstrate that this effect was due to plasma membrane cholesterol 
depletion and most likely subsequent disruption of lipid-rafts. Yet, the existence of a 
loop regulation in this regard is possible, in which the activity of the V-ATPase is 
further decreased by disruption of lipid-rafts. It has been shown by proteomic 
analysis, that several subunits of the V-ATPase are depleted from lipid-rafts by 
cholesterol-disrupting drugs, indicating a raft localization of the proton pump (70). A 
study by Lafourcade et al. showed that the membrane-integral V-ATPase subunits 
were associated with detergent resistant membranes, i.e. lipid-raft like domains, 
isolated from late endosomes. They could show that inducing cholesterol 
accumulation in late endosomes affected acidification, thereby raising the possibility 
that association with lipid-raft regulates V-ATPase activity. (71) Another study 
identified V-ATPase subunits in flotillin 1 enriched triton-insoluble domains of 
monocytes that can be thought of as lipid-rafts (72). Since it has also been reported, 
that the activity of the Na+/K+-ATPase is influenced by membrane cholesterol levels 
(73), one may hypothesize that the disruption of lipid-rafts by cholesterol depletion 
caused by V-ATPase inhibition in turn further decreases activity of the proton pump in 
the fashion of a positive feedback loop. However, the available data are scarce and 
further studies specifically addressing this matter are needed. 
Biophysical properties of the cell are greatly determined by the status of the 
cytoskeleton, which has been thoroughly studied yet remains unaffected in our study, 
but also by the plasma membrane composition, of which less is known (74-76). 
Investigating the membrane properties remains challenging, owing to the complex 
nature of their composition. Thousands of different lipid species build the backbone 
of cellular membranes and only due to advances in chromatographic, mass 
spectrometric and imaging techniques lipid bilayers can now be investigated in more 
detail. However, satisfying in vitro modification options for the plasma membrane 
composition are still largely missing (64) hence complicating functional membrane 
studies.  
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4.2. Cholesterol - an essential factor in cancer cell survival 
Cholesterol is a major component of the plasma membrane essentially regulating 
membrane fluidity, vesicle trafficking, endocytosis and receptor signaling. It has been 
reported, that cholesterol is crucial for the cytoskeletal adhesion to the plasma 
membrane in endothelial cells, thereby substantially regulating cell morphology and 
stiffness - properties that can be influenced by cholesterol depletion (77). In terms of 
cancer, studies revealed that lipid metabolism is deregulated in different cancers and 
that aberrant cholesterol metabolism in HCC seems to be a crucial factor in the 
malignant phenotype (45,66,78,79). In the present study, we could reveal that 
archazolid selectively reduces free cholesterol levels in HCC cell lines, but not in non-
malignant hepatocytes, reinforcing increased compliance and altered lipid 
metabolism as druggable characteristics of cancer cells in general.  
However, the mechanism of cholesterol reprogramming in cancer and subsequent 
effects still need to be fully examined (48). A study on primary tumor cells and HCC 
cell lines for instance showed that elevations in overall or mitochondrial cholesterol 
content were correlated with increased expression of the mitochondrial cholesterol–
transporting polypeptide steroidogenic acute regulatory protein (StAR) and 
chemotherapy resistance together with protection from apoptosis (42). Others 
reported, that increased mitochondrial cholesterol content due to mutations in the 
cholesterol export gene ABAC1 also reduced sensitivity to apoptotic signals (80), 
while contradictory results implicated STARD3, a lipid transfer protein, with poor 
prognosis in breast cancer (81). Of note, archazolid has been shown by our group to 
selectively induce apoptosis in tumor cells via induction of intrinsic apoptosis and 
cellular stress response (12). In context with the relevance of cholesterol for 
mitochondria, cellular cholesterol depletion as reported in this study might support 
induction of apoptosis by archazolid.  
Cholesterol homeostasis is tightly regulated in cells, by means of synthesis, 
esterification, metabolism, influx end efflux (34,81,82). The key regulator, that 
increases cellular cholesterol content is the transcription factor sterol-regulatory 
element binding protein 2 (SREBP-2), which leads to increased de novo synthesis as 
well as uptake of cholesterol containing lipoproteins and decreased efflux (81). Upon 
cholesterol depletion sensed by the ER membrane, SREBP-2 is transported to the 
Golgi for cleavage and subsequently its n-terminal, active form is translocated to the 
nucleus, where it induces transcription of HMGCR, LDLR and many other genes (34). 
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Recently, Hamm et al. connected archazolid treatment to an induction of cholesterol 
metabolism, stating that this is a main resistance mechanism of bladder cancer cells 
to the treatment (10). In accordance with their data, we found transcriptional induction 
of SREBP-2, HMGCR and LDLR. However, we draw different conclusions. For one, 
cholesterol is trapped in the lysosomes leading to depletion of the membrane and 
thereby alteration of biophysical characteristics and proliferative signaling, which we 
think is part of the drugs mechanism of action. Additionally, as we show that 
archazolid blocks LDLR internalization, upregulation of the protein should therefore 
have no functional consequences. For another, the feedback upregulation of 
cholesterol synthesis opens the possibility for a combination therapy with statins as 
discussed below. A combination therapy of archazolid with statins targets cholesterol 
metabolism in two different ways, thus enabling dose reduction of the single 
compounds while maintaining or even enhancing therapeutic effectiveness together 
with reduction of adverse effects.  
4.3. Blocking cholesterol uptake and synthesis - a combination 
therapy as promising anti-cancer strategy 
In the present work, we report V-ATPase inhibition as a novel way to achieve 
restriction of free cholesterol and lipid-raft disruption. As discussed above, alterations 
in cholesterol metabolism play a major role in cancer but exploitation as therapeutic 
target still remains challenging. Several different strategies to target aberrant 
cholesterol metabolism are currently under investigation: targeting cholesterol 
synthesis, reducing cholesterol uptake, interfering with intracellular cholesterol 
transport and inhibiting intestinal cholesterol absorption (81). For instance, a 
preclinical study showed a beneficial effect of ezetimibe, an inhibitor of intestinal 
cholesterol absorption, on prostate tumor growth (83). Also targeting prenylation by 
small molecules like an inhibitor of the geranylgeranyltransferase I or disruption of 
intracellular cholesterol transport by leelamine showed promising results (84,85). 
Leelamine is a lysosomotropic compound which inhibits cholesterol release from 
lysosomes and thereby causes membrane cholesterol depletion preferentially in 
cancer cells (85). In agreement with this finding, we observed that lysosomal trapping 
of cholesterol leads to a cholesterol depletion of the plasma membrane. We propose 
that archazolid targets cholesterol uptake by blocking LDL internalization and 
sequestering cholesterol within the lysosomes, thereby representing a new 
compound to target cellular cholesterol metabolism. 
DISCUSSION  65 
Extensive research has been done in evaluating the potential role of statins, 
cholesterol synthesis inhibitors, in cancer treatment, nevertheless the results remain 
controversial and further studies need to be performed (37,86). In the context of 
HCC, several studies show beneficial effects of statins either in single treatment or in 
combination treatment regimens (87). Sutter et al. for instance showed that various 
statins inhibited the proliferation of HCC by apoptosis induction and cell cycle arrest 
(88). Interestingly, Yang et al. found in a variety of different cell lines, that atorvastatin 
inhibits the growth of HCC, yet also induces autophagy as survival mechanism. In a 
combination therapy approach they blocked autophagy using the V-ATPase inhibitor 
bafilomycin, thereby enhancing atorvastatin-induced apoptosis (89). Along this line, 
we show that combining archazolid with simvastatin led to a synergistic enhancement 
of the anti-proliferative effect of archazolid single treatment. Additionally, apoptosis 
induction was increased by using the combination treatment. However, these effects 
were limited to our in vitro experiments. In our in vivo mouse xenograft model, we 
surprisingly found slightly induced tumor growth in simvastatin single treated mice 
and consequently no beneficial effect of a combination treatment. We hypothesize 
that this finding results from increased angiogenesis caused by simvastatin. 
Despite the existence of some pre-clinical studies that propose statins can inhibit 
tumor growth by reducing angiogenesis (90,91), others report pro-angiogenic 
properties of statins. Chen et al showed an improved outcome of rats suffering from 
stroke through administration of statins, which increased VEGF signaling and 
angiogenesis (92). In another study, Chade et al. showed that statins restore 
angiogenesis and attenuate intrarenal microvascular remodeling in a pig model for 
renal ischemia. In their study, simvastatin enhanced both intrarenal angiogenesis and 
arteriogenesis by increasing angiogenic growth factor expression and hypoxia-
inducible factor-1α signaling (93). Interestingly, a biphasic dose-dependent effect of 
statins on angiogenesis has been reported by Weis et al. In their study on endothelial 
cells, they found angiogenesis promoting effects at low therapeutic concentrations 
but in contrast angiostatic effects at high concentrations. (94) The presence of such a 
dose-dependency could explain our observation of a clear anti-cancer effect in vitro, 
but not in vivo. In our in vitro experiments we only assessed the effect of simvastatin 
on cancer cells, while i.p. administration in vivo also targets endothelial cells. We 
hypothesize that the simvastatin plasma levels in our mouse model favored 
angiogenesis, which subsequently promoted tumor cell growth in a greater extent 
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than the growth inhibitory effect on the cancer cells directly. However, further data 
addressing this discrepancy is needed to draw a final conclusion. 
This study and the data of others provide strong experimental evidence for the use of 
statins to treat HCC, yet like in our mouse model, the situation in vivo, especially in 
humans is vastly more complex. There are several human studies which evaluated 
the potential effect of statins on the development and treatment of HCC, of which 
some report a promising statin effect (87,95). However, more randomized controlled 
trials are necessary to clarify the role of statins in HCC. 
In conclusion, our observation of synergistic growth inhibition by targeting the 
cholesterol metabolism in two ways, together with the research of others strongly 
suggest that a combination therapy approach might be superior to single agents in 
the treatment of HCC. Yet, dosage and treatment regimens still need further 
evaluation.  
4.4. Inhibition of Ras signaling - new treatment option for an old 
oncogene 
We report a change in biophysics and cholesterol metabolism upon V-ATPase 
inhibition, yet to our knowledge little to nothing is known on how this could influence 
proliferation of human cells. Interestingly, Atilla-Gokcumen et al. recently found first 
evidence, that cells tightly regulate lipid species and localization during the cell cycle 
by excessive feedback loops, leading to variations in cell stiffness along the cell cycle 
(96). This finding raises the question, on whether proliferative signaling is influenced 
by stiffness alterations. As an essential component of lipid-rafts, cholesterol has 
already been implicated in the regulation of different signaling pathways in cell 
survival and apoptosis. Cholesterol depletion in fibroblasts led to an induction of 
caspase 3 activity and apoptosis via a RhoA and p38 MAPK dependent pathway 
(49), which goes in line with the finding that Fas and TRAIL dependent apoptosis are 
lipid-raft dependent in cancer cells (48). Also anoikis-like apoptosis via FAK down-
regulation has been observed upon cholesterol depletion and subsequent disruption 
of caveolae, a sub-type of lipid-rafts. (97). Yet, in our study a different mechanism 
must be present. On the one hand, we only see mild induction of apoptosis with a 
maximum of about 25 % in combination treatment with archazolid and simvastatin 
and on the other hand due to the fact that HUH-7 and HepG2 cells do not express 
caveolin (98). Additionally, cell survival is greatly determined on growth factor 
receptor signaling, like the insulin receptor and the EGF receptor (EGFR), which 
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have been reported to be regulated by cholesterol (44). EGFR dimer formation and 
the following autophosphorylation of was modulated by cholesterol (44). In an earlier 
study by our group we could also observe mislocalization of EGFR and a reduction of 
Rac1 dependent regulation after V-ATPase inhibition (23) however, the effects of 
cholesterol were not investigated in this study. Noteworthy, EGFR activation leads to 
an induction of proliferative Ras signaling.  
The Ras family of small GTP-ases, was among the first proteins identified with the 
ability to induce cell growth and soon discovered to be aberrant in tumor cells (50). 
Ever since, many approaches have been made to specifically target de-regulated 
Ras signaling, but so far still face major drawbacks. This is caused by the enormous 
complexity of Ras signaling and activation, which is why Ras is still considered 
‘undruggable’ (99). Major problems in finding small-molecule inhibitors are the high 
similarity amongst Ras family members and the fact that one Ras protein usually has 
several regulators, as well as several effectors (100). Yet, a more promising way in 
targeting Ras might be interfering with Ras localization (99), as it has become evident 
that different Ras isoforms are targeted to distinct membrane localizations and cause 
different activation of downstream effectors (52,100,101).  
In mammalian cells, three different genes code for four proteins of the Ras family: H-
Ras, N-Ras and two different splice variants of K-Ras (K-Ras4A and K-Ras4B) (101). 
There is significant variation in the contribution of Ras isoforms to the total aberrant 
Ras activation in different cancer cell lines, however, the major mutated isoform is K-
Ras, followed by N-Ras and last H-Ras (102). Nevertheless, in HCC Ras is only 
mutated in few cases and rather downstream signaling is altered (53,54). 
Interestingly, there is now evidence that the different isoforms, which have long been 
thought to signal mainly form plasma membrane locations, are specifically targeted to 
specific endomembranes and different sites within the plasma membrane and that 
correct localization is essential to facilitate a variety of downstream signals (52,101). 
Nevertheless, there is still controversy as to which isoform is located at which 
membrane and how localization is linked to different downstream signaling (103).  
Targeting of Ras to specific membrane sites is achieved by posttranslational 
modification of the proteins. All three Ras proteins undergo prenylation at their 
conserved C-terminal CAAX motif (C is cysteine, A is any aliphatic amino acid and X 
represents any amino acid), leading to ER targeting. N-Ras, H-Ras and K-Ras4A are 
additionally palmitoylated in the Golgi apparatus and transferred to the plasma 
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membrane, whereas K-Ras4B does not need additional palmitoylation as its 
membrane binding is mediated via a polybasic, lysine-rich region. (104) Besides 
signaling from plasma membrane locations, Ras signaling can also take place on 
membranes of the Golgi apparatus, the ER and mitochondria each having a different 
signaling outcome (50,101,105-108). Studies specifically evaluating plasma 
membrane Ras signaling show that N-Ras and H-Ras are dependent on a functional 
endocytosis pathway, while K-Ras signaling is not (102,103). In this regard another 
study reports that EGF activates N-Ras, but not K-Ras, however is enabled to 
activate both upon cholesterol depletion (100).  
We report that upon V-ATPase inhibition the activation of Ras is diminished, leading 
to impaired downstream signaling namely Raf/MEK/ERK. Yet, we did not distinguish 
between different Ras isoforms or mutation status. Our study also shows that Ras 
signaling from plasma membrane lipid-rafts is inhibited by cholesterol depletion as 
external cholesterol supplementation restored Ras activation. The independence of 
K-Ras signaling form cholesterol depletion (102,103) might be the reason why the 
PI3K/Akt pathway in our experiment was not affect though. Yet there is still 
controversy on which Ras isoforms are more prone to activate Raf-1 or PI3K 
respectively. While Yan et al. report that K-Ras preferentially induces Raf-1 and H-
Ras PI3K (109), Matallanas et al. state that Raf-1 is mainly activated at lipid-rafts 
(107). So it still has to be clarified which Ras isoform is responsible for the effect we 
report. Furthermore, cell types with different Ras mutation status should be analyzed 
to assess, whether our findings provide a therapeutic approach for tumors with 
specific Ras mutations. Reduced Ras/Raf/MEK/ERK signaling led to a reduction in 
proliferation in vitro and in vivo in our experiments, possibly indicating that inhibition 
of plasma membrane originated Ras signaling is mainly affected as Golgi apparatus 
dependent Ras signaling has been reported to be insufficient to promote cell 
proliferation (107).  
We think that our results display V-ATPase inhibition as novel option to target lipid-
raft dependent Ras signaling ultimately upstream, thereby avoiding specificity and 
pathway cross talk problems with small molecule inhibitors.  
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4.5. Concluding remarks and future perspectives 
Despite intensive research, new strategies for treatment of HCC are still lacking. 
While research in the past mostly focused on direct inhibition of oncogenic signaling, 
targeting cancer cell lipid and cholesterol metabolism, especially in HCC is gaining 
interest. In the present work, we identified new treatment options for HCC by 
combining biophysical and cell-biological methods. We demonstrate for the first time 
that the V-ATPase inhibitor archazolid leads to lysosomal trapping of cholesterol, 
thereby altering cell stiffness and membrane fluidity. This subsequently leads to 
decreased proliferation by interference with membrane-related signaling of the well-
known oncogene Ras (Fig 25). The in vivo efficacy of archazolid in a mouse 
xenograft HCC model seems to be based on cholesterol trapping as well. 
Importantly, non-malignant hepatocyte-like cells are not affected by the drug. We 
propose targeting cholesterol metabolism by V-ATPase-inhibition to be an attractive 
therapeutic strategy against HCC, which especially might overcome the present 
challenges in targeting oncogenic Ras signaling. 
In a combination therapy approach, we applied the cholesterol synthesis inhibitor 
simvastatin together with archazolid and could report synergistic inhibition of cell 
proliferation and induction of apoptosis in vitro. Yet, the approach failed to be 
beneficial in our mouse model, which might be attributed to a pro-angiogenic effect of 
simvastatin. In conclusion, we think that a combination therapy of archazolid and 
simvastatin could target cholesterol metabolism and oncogenic Ras signaling in 
multiple ways and enhance the therapeutic effectiveness (Fig 25). However, future 
research needs to be done to fine-tune dosage and treatment regimen.  
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Figure 25 Proposed mechanism of action (A) Under physiological conditions LDL binds to its 
receptor and is internalized. The V-ATPase acidifies the endo-lysosome, leading to LDL dissociation 
from the receptor and cleavage. Free cholesterol is then released into the cytosol and is used as 
building block and for the integration into membranes. Furthermore, cholesterol is synthesized in the 
cytosol via the mevalonate pathway (brown bullets). Ras is a membrane-bound small GTPase mainly 
localized in cholesterol-enriched membrane microdomains, where it can be activated. Ras in turn 
activates different signaling pathways leading to proliferation and tumor growth. (B) Upon inhibition of 
the V-ATPase by Archazolid, LDLR internalization and acidification of the endo-lysosome is inhibited, 
causing subsequent accumulation of cholesterol within the lysosomes. Due to blocking the conversion 
of HMG-CoA to mevalonate by simvastatin, de novo synthesis of free cholesterol is inhibited. The lack 
of free cholesterol leads to cholesterol depletion of the membrane and subsequently a disruption of 
cholesterol-enriched microdomains and a change in membrane properties. As a counsequence, 
cholesterol microdomain-dependent Ras cannot be activated anymore and downstream signaling is 
inhibited, leading to reduced proliferation and tumor growth. Mev Mevalonate, GPP 
geranylpyrophosphate, FPP farnesylpyrophosphate, Sq Squalene, Lano Lanosterol, GEF guanosyl-
exchange factor, GAP GTPase activating protein, LDL(R) low density lipoprotein (receptor) 
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6. APPENDIX 
6.1. Abbreviations 
°C degree Celsius 
µg/mg/kg micro/milli/kilo gram(s) 
µl/ml micro/milli liter(s) 
Akt protein kinase B 
arch archazolid 
ATP adenosine tripohsphate 
Bad Bcl-2-antagonist of cell death 
BC  bichinchoninic acid 
BSA bovine serum albumine 
CE cholesteryl ester 
CO2 carbon dioxide 
CoA coenzyme A 
d day(s) 
DMEM dulbecco’s modidfied eagle medium 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
DTT dithiotherithol  
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
EGF(R) epidermal growth factor (receptor) 
EGTA ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
ER endoplasmatic reticulum 
ERK extracellular signal-regulated kinase 
FAK focal adhesion kinase 
Fas a transmembrane protein of the tumor necrosis factor family 
FCS fetal calf serum 
FRAP fluorescence recovery after photo-bleaching 
g gravity  
Ga gauge 
GAP GTP-ase activating protein 
GDP guanosine diphosphate 
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GEF guanosyl-exchange factor 
GFP green fluorescent protein 
GP generalized polarization 
GRB2 Growth factor receptor-bound protein 2 
GTP guanosine triphosphate 
h hour(s) 
H2O2 hydrogen peroxide 
HCC hepatocellular carcinoma 
Hep3B liver cancer cell line 
HepG2 liver cancer cell line 
hHep primary human hepatocytes 
HMG-CoA 3-Hydroxy-3-Methylglutaryl-CoA 
HMGCR 3-Hydroxy-3-Methylglutaryl-CoA reductase 
Hoechst Hoechst 33342, bisBenzimide 
HRP horseradish preoxidase 
HUH-7 liver cancer cell line 
i.p. intra peritoneal 
IHC immune histochemistry 
LAMP-1 lysosomal-associated membrane protein 1 
LDL (R) low density lipoprotein (receptor) 
LX-R liver X receptor 
MEK mitogen-activated protein kinase kinase 
min minute(s) 
mRNA messenger RNA 
n/cm nano/centi meter(s) 
Na3VO4 sodium orthovanadate 
NaCl sodium chloride 
NaF sodium fluoride 
nM/µM/mM nano/micro/milli molar 
P phosphate 
P/S penicillin streptomycin 
p38 MAPK p38 mitogen-activated protein kinase 
PBS phosphate buffered saline 
PFA para formaldehyde 
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PI propidium iodide 
PI3K phosphoinositide 3-kinase 
PLCε 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase 
epsilon 
PMA phorbol myristate acetate 
PMSF phenylmethylsulfonylfluorid 
PP pyrophosphate 
qPCR quantitative real-time polymerase chain reaction 
Raf rapidly accelerated fibrosarcoma or rat fibrosarcoma 
RalGDS Ral guanine nucleotide dissociation stimulator 
Ras rat sarcoma 
RhoA Ras homolog gene family member A 
RNA ribonucleic acid 
rpm rotations per minute 
RT-DC real-time deformability cytometry 
s second(s) 
SCID severe combined immune deficiency 
SDS sodium dodecyl sulfate 
siRNA small-interfering RNA 
SOS son of sevenless 
SREBP-2 sterol-regulatrory element binding protein 2 
STR short tandem repeat 
TCE tricholoroethanol 
TRAIL tumor necrosis factor related apoptosis inducing ligand 
U/ml unit per milliliter 
V-ATPase vacuolar-type ATPase 
VLDL very low density lipoprotein 
w/v weigth per volume 
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